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9Abstract
Prostate cancer is the most common cancer in males and a major cause of cancer death in industrial-
ized countries. It is generally a very slowly growing cancer and potentially curable at early stages 
by radical prostatectomy or radiotherapy. However, radical therapy is associated with side effects. 
Therefore, there is need for novel treatments for advanced prostate cancer, and for curing or slowing 
down the growth of the tumors.
 Proteases play important roles in the progression of prostate and other cancers. Prostate produces 
high levels of two kallikreins, human kallikrein 2 (hK2, kallikrein-related peptidase 2, KLK2) and 
prostate specific antigen (PSA, KLK3). These proteases are secreted into seminal fluid and mediate 
liquefaction of the seminal clot that forms after ejaculation. Furthermore, enzymatically active PSA 
has been shown to reduce angiogenesis in vitro and in vivo, which may contribute to the slow growth 
of prostate cancer. PSA expression is lower in malignant than in normal prostatic epithelium. It is 
further reduced in poorly differentiated tumors, in which the expression of hK2 is increased. hK2 may 
mediate tumor growth and invasion by participating in proteolytic cascades degrading extracelullar 
matrix and thereby promoting tumor spread. Both PSA and hK2 degrade insulin-like growth factor-
binding protein-3 (IGFBP-3) in vitro. IGFBP-3 is an important regulator of cell proliferation and 
survival via IGF-system, and independently. hK2 is more potent than PSA in degrading IGFBP-3. 
Because its expression is increased in prostate cancer, degradation of IGFBP-3 by hK2 locally in the 
prostate may promote prostate cancer growth.
 By using phage display technology we developed biologically active peptides, which specifically 
inhibit the enzymatic activity of hK2. The peptides were characterized and the motifs required for 
their inhibitory activity were determined. These may be used to target hK2 for treatment and their 
binding property be utilized in tumor imaging. However, the peptides were degraded in plasma within 
minutes and thus, have limited use in vivo. By head-to-tail cyclization we were able to improve plasma 
stability of the original linear hK2-inhibiting peptide, while the activity towards hK2 was retained. 
 When secreted from the prostate, most of PSA is free and enzymatically active. In circulation 
major portion of PSA occurs in complexes with protease inhibitors and, thus, is inactive. To justify the 
use of mouse models for evaluation of the function of PSA and for studies in therapeutic modalities 
based on modulation of PSA activity it is important to know whether PSA complexation is similar in 
mouse and man. We characterized the circulating forms of PSA in mouse, by directly adding to mouse 
serum or using subcutaneous PSA-producing human prostate cancer cell xenograft tumor models. 
When added to mouse serum, over 70% of PSA forms complexes within 30 min. The complexes 
contained α2-macroglobulin and serpins of the α1-antitrypsin (AAT) family. Thus, in mouse serum, 
PSA forms complexes similar to those in man, but the major immunoreactive complex contains AAT 
rather than α1-antichymotrypsin (ACT). In mice bearing LNCaP xenograft tumors 70% of immunore-
active PSA occurs in complex with AAT. Hence, the metabolism of PSA produced by xenograft tumor 
models in mice is similar to that of human prostate tumors with respect to the fate of released PSA and 
would allow the evaluation of treatment modalities based on PSA activity.
 We studied the degradation of IGFBP-3 by hK2 and identified the cleavage sites by mass 
spectrometry. Furthermore, we showed that hK2-inhibiting peptides inhibit hK2 activity towards 
natural protein substrates, including IGFBP-3. As degradation of IGFBP-3 leads to release of IGF-I, 
which may stimulate cancer growth, these peptides may be useful for treatment of prostate cancer 
and other diseases associated with increased hK2 activity. 
 The peptides identified in this study have potential therapeutic value for treatment of prostate 
cancer. They can also be used as lead molecules for the development of peptide analogues suitable 
for imaging and treatment of prostate cancer.
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1. The Prostate and Prostate Cancer
The main function of the prostate is to 
produce part of seminal fluid, which 
carries spermatozoa during ejaculation. 
Within the prostate, the major fraction of 
seminal fluid is produced by the luminal 
cells of glandular acini (Huggins et al. 
1942). These epithelial cells, together with 
the stromal cells, contain cytoplasmic 
androgen receptors (Chatterjee 2003). 
Androgens are the major stimulators of 
prostate growth (Wilson & Foster 1985). 
They regulate the expression of several 
prostatic proteins, including proteases such 
as human kallikrein 2 (hK2, kallikrein-
related peptidase 2, KLK2) and prostate 
specific antigen (PSA, KLK3) (Clements 
1989; Grauer et al. 1996; Young et al. 1992; 
Lawrence et al. 2010). 
 Prostate cancer is the most common 
non-skin cancer in industrialized countries 
and the second leading cause of cancer 
deaths among men (Jemal et al. 2010). In 
most cases the growth of prostate tumors 
is a slow process and most tumors remain 
indolent during the lifetime of a man, and 
therefore, many tumors do not require 
clinical attention and treatment (Stenman 
et al. 1999a; Choo et al. 2002; Klotz 2003). 
 The mechanisms behind the initiation 
of prostate cancer are largely unknown 
(Shen & Abate-Shen 2010). Some candidate 
oncogenes, tumor suppressor genes, 
and genomic rearrangements associated 
with the development of prostate cancer 
have been identified. For example, loss of 
tumor suppressor gene phosphatase and 
tensin homolog (PTEN) (Salmena et al. 
2008), loss-of-function of homeobox gene 
NK3 transcription factor related locus 1 
(NKX3.1) (Abate-Shen et al. 2008), Serine 
Protease Inhibitor Kazal-type 1/Tumor-
Associated Trypsin Inhibitor (SPINK-1/
TATI) overexpression (Paju et al. 2007; 
Tomlins et al. 2008; Ateeq et al. 2011), 
gene fusions of Transmembrane Protease, 
Serine 2 (TMPRSS2) and E-Twenty 
Six (ETS) family members, especially 
TMPRSS2-ERG and TMPRSS-ETV1 and -4 
(Tomlins et al. 2007; Tomlins et al. 2009), 
and fusion of KLK2 with ETV4 (Hermans 
et al. 2008) are associated with prostate 
cancer. A large scale segregation study on 
twins shows that hereditary factors could 
contribute to the development of up to 
42% of prostate cancers (Lichtenstein et al. 
2000). Genome-wide studies have revealed 
several loci containing susceptibility genes 
for hereditary prostate cancer. (Smith et al. 
1996; Xu et al. 1998; Wiklund et al. 2003; 
Schleutker et al. 2003). In addition, several 
polymorphisms associated with prostate 
cancer have been found (Thomas et al. 
2008). These include single nucleotide pol-
ymorphism (SNP) in the genes that encode 
PSA (KLK3), ß-microseminoprotein 
(ß-MSP, MSMB) and hK2 (KLK2) (Nam et 
al. 2003; Severi et al. 2006; Eeles et al. 2008; 
Liu et al. 2011).
1.2. Prostate Cancer Diagnosis and 
Screening
Prostatic intraepithelial neoplasia (PIN) 
may develop already at 20-30 years of 
age, while the presence of microscopic 
prostatic tumors can be observed in the 
next and later decades of life (Sakr et al. 
1993). More than 50% of men over 60-80 
years of age have an occult prostate cancer 
(Franks 1954; Sakr et al. 1999). A slowly 
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growing prostate cancer has an average 
doubling time of 2 to 4 years (Schmid et 
al. 1993). Early stage tumors with a size up 
to one gram do not usually cause clinical 
symptoms (Stamey et al. 1987; Stenman 
et al. 2000). A one gram tumor increases 
serum PSA on average by 2-3 µg/l. Thus, 
detection of such cancers is possible by 
determination of PSA in serum combined 
with digital rectal examination (DRE) 
and needle biopsy guided by transrectal 
ultrasonography (TRUS) (Catalona et al. 
1997; Ornstein et al. 1997; Stenman et 
al. 1999a). Prostate cancer diagnosis is 
based on examination of tissue obtained 
by needle biopsy. Tumor aggressiveness is 
evaluated by a grading system established 
by Gleason (Gleason & Mellinger 1974). 
A grade of 1 to 5 is assigned based on the 
glandular architecture, where lower grades 
indicate well differentiated and higher 
grades poorly differentiated glandular 
structure. The Gleason score is calculated 
as the sum of the grades of the two most 
prevalent tumor patterns. The scale is from 
2 to 10, and a Gleason score below 6 is 
classified as a low grade prostate cancer, 
7 is an intermediate grade and above 7 is 
a high grade prostate cancer. The tumor 
node metastasis (TNM) system is used 
for staging of prostate cancer. This system, 
maintained by American Joint Committee 
on Cancer (AJCC) and International 
Union for Cancer Control (IUCC), is the 
most commonly used staging method. The 
TNM system classifies cancers based on the 
size and extent of the primary tumor (T), 
spread into lymph nodes (N) and distant 
metastases (M) (Table 1). This information 
can be used to group tumors in 4 stages 
described by Roman numerals with added 
letters for defining substages, i.e, stage I, 
II, III, IV and substages like stage IIA, IIB, 
etc. Based on this, stage III refers to locally 
advanced cancer and stage IV to metastatic 
cancer. If available the TNM information 
can be combined with Gleason score and 
serum PSA for tumor staging.
 Prostate cancer can be detected at 
an early stage by screening based on de-
termination of serum PSA and biopsy of 
men with elevated values of PSA (Stamey 
et al. 1987; Catalona et al. 1991; Brawer et 
al. 1992; Oesterling et al. 1995; Stenman et 
al. 2005; Lilja et al. 2008). Trial studies on 
screening of prostate cancer are ongoing in 
Europe and USA. The largest ones are “The 
European randomized study of screening 
for prostate cancer (ERSPC)” and “the 
Prostate, Lung, Colorectal, and Ovarian 
(PLCO) Cancer Screening Trial”. These 
trials randomly assign men aged between 
50 and 74 for a PSA test (Andriole et al. 
2009; Schröder et al. 2009). The European 
study has shown that PSA based screening 
reduces mortality. But it also causes over-
diagnosis, i.e., it detects prostate cancers 
in men, who would not develop clinical 
disease within their lifetime (Draisma 
et al. 2003). This leads to unnecessary 
treatments, which may have serious side 
effects. Therefore, there is a need for 
strategies that more accurately differentiate 
between tumors that do and do not need 
treatment. Traditionally, a cut-off level of 
4 µg/l serum PSA has been used to detect 
prostate cancer. However, moderately 
elevated PSA levels (4-10 µg/l), so called 
“grey zone”, in serum do not always indicate 
malignancy, but may be caused by other 
prostate related diseases, especially benign 
prostatic hyperplasia (BPH) (Stamey et al. 
1987; Stenman et al. 1999a). Patients with a 
concentration of serum PSA exceeding 10 
µg/l have more than a 50% risk of harboring 
prostate cancer (Armitage et al. 1988). 
However, a serum PSA below 4 µg/l does 
not exclude the presence of malignancy, 
thus, men with PSA values below 4 µg/l 
were found to have 15% risk of having a 
prostate cancer (Thompson et al. 2004). 
 To improve the diagnostic accuracy of 
PSA, subfractions of PSA, like complexed 
and free PSA (Stenman et al. 1991; Lilja et 
al. 1992; Christensson et al. 1993), proPSA, 
nicked PSA and intact PSA (Mikolajczyk 
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et al. 2002; Mikolajczyk et al. 2004; Lilja et 
al. 2008) can be measured, and parameters 
like PSA doubling time (Schmid et al. 
1993), PSA velocity (Carter et al. 1992), 
PSA density (Benson et al. 1992) and 
age specific PSA values can be calculated 
(Oesterling 1994; Oesterling et al. 1995). 
The most commonly used method to 
improve the accuracy of PSA test is to 
analyze free PSA and calculate the ratio of 
free to total PSA (percent free PSA, %fPSA) 
in serum (Finne et al. 2002). %fPSA signifi-
cantly improves discrimination between 
malignant disease and BPH (Stenman 
et al. 1991; Christensson et al. 1993; Lilja 
& Stenman 1996). An elevated serum 
PSA and a low %fPSA indicate increased 
risk of prostate cancer as compared to 
elevated PSA alone (Stenman et al. 1994). 
In serum, the proportion of a 2 amino acid 
truncated isoform of proPSA, named [-2]
proPSA (p2PSA), has been found to be 
higher in prostate cancer compared with 
BPH (Mikolajczyk et al. 2001). p2PSA also 
has been shown to significantly improve 
prostate cancer detection (Stephan et al. 
2009; Sokoll et al. 2008) when used for 
calculation of the prostate health index 
(PHI). PHI, calculated using the serum 
concentrations of p2PSA, fPSA and tPSA 
by the formula (p2PSA/fPSA) x √(tPSA) 
(Jansen et al. 2010), has been suggested to 
be a strong predictor of prostate cancer in 
men with PSA serum levels of 2-10 µg/l 
(Guazzoni et al. 2011).
 The serum levels of hK2 have been 
shown to add prognostic value for organ 
confined prostate cancer in men with PSA 
serum levels of 4-10 ng/ml (Recker et al. 
2000; Haese et al. 2001; Raaijmakers et al. 
2007). Combining serum concentrations 
of free and total PSA with hK2 provides 
further information about the pathologic 
stage of clinically localized prostate cancer 
(Steuber et al. 2007; Lilja et al. 2008). A 
statistical model to predict the results of 
prostate biopsy has been developed on 
the basis of blood levels of total PSA, free 
PSA, intact PSA and hK2 (Vickers et al. 
2008). Here, intact PSA assay measures 
free PSA that is not cleaved at lysine-145 
and lysine-146 (Väisänen et al. 2006). This 
4-kallikrein panel is a strong predictor of 
prostate cancer in men with elevated serum 
PSA levels (Vickers et al. 2011). Recently, 
serum/plasma markers have been used 
also in combination with prostate cancer 
associated SNP’s in the genes that encode 
PSA, hK2 and MSP (Klein et al. 2010).
1.3. Prostate Cancer Treatment
Treatment options for prostate cancer 
depend on the stage of the tumor. Surgery 
or radiation therapy are mostly curative 
when the tumor is detected at a localized 
stage. Surgery permits precise clinical 
staging and complete removal of the 
tumor. However, it may cause serious side 
effects such as incontinence, impotence 
and complications related to the operation 
(Begg et al. 2002). Radiation therapy is less 
strenuous than surgery, but it may also lead 
to impotence and harm nearby organs like 
the bladder and rectum (Pollack et al. 2002; 
Stone & Stock 2007).
 In men with prostate cancer at 
stages III or IV, the treatment options 
include radiation and hormone ablation. 
Like the normal prostate, development 
of prostate cancer in the early stages is 
androgen dependent and can therefore 
be treated by androgen ablation (Huggins 
& Hodges 1941). Hormone treatment 
options include surgical castration, the 
use of antiandrogens, luteinizing hormone 
releasing hormone (LHRH) analogues 
or combinations of these for maximal 
androgen blockade. These methods either 
prevent androgen secretion or block the 
growth stimulating effect of androgens. 
Most cases initially respond to hormone 
therapy by stopping tumor growth, but 
androgen-resistance develops if the patient 
lives long enough. Several drugs can be 
used to treat castration resistant prostate 
cancer, such as MDV3100, an androgen 
13
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Table I : TNM staging system of prostate cancer
Evaluation of the primary tumor (‘T’)
TX Tumor cannot be assessed
T0 Tumor is not present
T1 Tumor present, but not clinically detectable
T1a Tumor	incidental	histologic	finding	in	≤ 5% of resected tissue; not palpable
T1b Tumor	incidental	histologic	finding	in	>	5%	of	resected	tissue
T1c Tumor	identified	by	needle	biopsy	(due	to	elevated	serum	PSA)
T2 Tumor is palpable
T2a Tumor is in one-half of one lobe or less
T2b Tumor is in more than one-half of one lobe but not in both lobes
T2c Tumor is in both lobes
T3 Tumor is spread through the prostatic capsule
T3a Unilateral or bilateral extracapsular extension
T3b Tumor invades seminal vesicles
T4 Tumor invades nearby adjacent structures
Evaluation of the regional lymph nodes (‘N’)
NX Nodes cannot be assessed
N0 No regional node metastasis
N1 Node metastasis is present
Evaluation of distant metastasis (‘M’)
MX Metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis is present
M1a Metastasis to distant lymph nodes
M1b Metastasis to bone
M1c Metastasis	to	other	sites	(e.g.	liver,	lung)
Adapted from Greene FI, Page DL, Fleming ID, et al.: AJCC Cancer Staging Manual, 6th ed. 
New York, Springer-Verlag, 2002, p.223
receptor antagonist (Tran et al. 2009), 
Abiraterone, an inhibitor of the CYP17A1 
enzyme that converts testosterone to 
dihydrotestosterone (de Bono et al. 
2011), and docetaxel, a mitosis inhibitor 
belonging to the taxane-group (Tannock 
et al. 2004). These may provide short term 
effects on survival. Recently, FDA (U.S. 
Food and Drug Administration) approved 
immunotherapy based treatment called 
14
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sipuleucel-T that can be used to treat 
castration resistant prostate cancer (Kantoff 
et al. 2010). It enhances the potency of 
the immune response to prostatic acid 
phosphatase (PAP), which is expressed in 
~95% of prostate cancers (Higano et al. 
2010; Patel & Kockler 2008). The vaccine 
contains immunostimulatory dendritic 
cells of the patients that have been activated 
with a recombinant fusion protein of 
PAP and granulocyte–macrophage 
colony-stimulating factor (GM-CSF), an 
immune cell activator (Higano et al. 2010). 
According to the IMPACT trial study this 
therapy increased overall survival of the 
patients from 21.7 to 25.8 months (Kantoff 
et al. 2010). However, the treatment 
requires leukapheresis, and it does not 
eradicate prostate cancer completely.
2. The Tissue Kallikrein Family
The human tissue kallikrein family of 
serine proteases consists of 15 members. 
The first kallikrein was discovered in 1930 
as a pancreas-derived cardioactive and 
vasoactive substance (Kraut et al. 1930; 
Lundwall & Brattsand 2008). It is presently 
known as tissue kallikrein 1 or kallikrein 
1 (KLK1). The effect of kallikrein was 
attributed to the release of kinin peptides 
from kininogens (Bhoola et al. 1992). Sub-
sequently another enzyme was discovered 
to have similar function and was named 
plasma kallikrein (KLKB1) (Chung et al. 
1986). Although both of these enzymes 
are serine proteases that show similar 
kininogenase activity, they have different 
expression profiles, protein structure and 
substrate specificity (Lundwall & Brattsand 
2008). The KLKB1 gene is located in 
chromosomal region 4q34-35, and it is 
not a member of human tissue kallikrein 
family. The KLK1 gene that transcribes 
kallikrein 1 is located together with the 
14 other tissue kallikreins, known as kal-
likrein-related peptidases 2-15 (KLK2-15), 
in a gene cluster at chromosomal region 
19q13.3-13.4. (Harvey et al. 2000; Gan 
et al. 2000; Yousef et al. 2000; Lundwall 
et al. 2006) (Figure 1). The transcription 
direction of most KLKs is from telomere 
to centromere, except hK2 (KLK2) and 
PSA (KLK3), which are transcribed 
from centromere to telomere. The first 
identified kallikreins, the so-called classical 
kallikreins, KLK1, hK2 and PSA contain 
a unique 11 amino acid long kallikrein 
loop and share a higher degree of amino 
acid sequence similarity of 62-79% than 
KLK4-15, which share 25-49% sequence 
similarity (Villoutreix et al. 1994; Harvey 
et al. 2000). Within the kallikrein locus, the 
genes for hK2 and PSA are located in close 
proximity and their active forms have 79% 
sequence similarity. In contrast to humans, 
mouse or rat kallikrein loci do not contain 
functional KLK2 and KLK3 genes, but only 
KLK2 pseudogenes (Pavlopoulou et al. 
2010).
 All KLK genes express single chain 
serine proteases containing a catalytic 
triad consisting of aspartate-57, histidine-
102 and serine-195 (numbering of amino 
acids according to bovine chymotrypsin). 
All KLKs have either trypsin- or chy-
motrypsin-like substrate specificity. The 
kallikreins are transcribed as proenzymes 
with a signal peptide, which is cleaved 
off prior to the transportation from the 
endoplasmic reticulum into secretory 
granules (Lawrence et al. 2010). They 
contain 3 to 37 amino acid long activation 
peptides or pro-peptides ending with 
lysine or arginine, which suggests that 
the zymogens are activated by enzymes 
with trypsin-like specificity (Paliouras 
& Diamandis 2006). Kallikreins have 
been shown to activate each other and 
are also activated by plasmin, urokinase, 
thrombin, factor Xa, plasma kallikrein and 
trypsin (Takayama et al. 1997; Paju et al. 
2000; Yoon et al. 2008). hK2 cleaves the 
activation peptides of both prohK2 and 
proPSA, thereby activating itself and PSA 
(Mikolajczyk et al. 1997; Lövgren et al. 
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1997; Denmeade et al. 2001a; Williams et 
al. 2010). PSA has also been shown to be 
activated by trypsin, prostasin and several 
other kallikreins (Takayama et al. 1997; 
Paju et al. 2000; Takayama et al. 2001; Yoon 
et al. 2008). The fact that several kallikreins 
are substrates for other kallikreins and 
they are co-expressed in some tissues, like 
prostate and skin, suggests the existence 
of so-called kallikrein activation cascade 
(KLK activome) (Figure 2) (Paliouras & 
Diamandis 2006; Pampalakis & Sotiropou-
lou 2007).
 Several KLKs are expressed in the 
Figure 1. KLK locus, gene and protein form. a) The KLK gene is located in the long arm of 
chromosome 19 in region 13.4. The direction of gene transcription is from telemore to centromere 
except KLK2 and KLK3. The “classical” KLK genes (KLK1, -2 and -3) are shown in black, whereas 
KLK4-15 shown in grey and KLK1 pseudogene in light grey. b) KLK genes consist of 5 coding 
exons and 4 intervening introns with a conserved intron phase of I, II, I, 0. The codons for the 
residues of catalytic triad are conserved, histidine (H) near the end of coding-exon 2, aspartic acid 
(D) in the middle of coding-exon 3, and serine (S) near the start of coding-exon 5. Most KLK genes 
include also one or two non-coding exons in the 5´ and 3´ untranslated regions (UTR). c) KLK 
proteins are translated as pre-proenzymes, of which the signal sequence (Pre) is cleaved of prior 
to transportation from endoplasmic reticulum for secretion. propeptide (Pro) remains until the 
activation of the KLKs. Modified and adapted from Borgoño and Diamandis 2004 Nat Rev Cancer 
4(11), pp.876–890.
prostate and are present in seminal fluid at 
various concentrations. Among these, hK2 
and PSA are most abundantly produced 
by prostatic epithelial cells (Wang et al. 
1981; Schedlich et al. 1987). Within the 
prostate, the expression of hK2 and PSA 
is regulated by androgens through the 
androgen receptor (AR) (Lawrence et al. 
2010). AR elements (ARE) are located in 
the PSA promoter region (Riegman et al. 
1991a; Riegman et al. 1991b; Cleutjens et 
al. 1997). The highest concentrations of 
hK2 and PSA are found in seminal plasma 
and prostatic extracellular fluid, but they 
are also present at lower concentrations in 
breast milk, breast cytosol, breast cyst fluid, 
saliva, urine and plasma (Clements 1989; 
Denmeade et al. 2001b; Shaw & Diamandis 
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2007; Emami et al. 2009). hK2, PSA, 
KLK5 and -14 are directly or indirectly 
involved in the degradation of semeno-
gelins, which are the main gel-forming 
proteins of seminal plasma. Proteolysis of 
the gel is mainly carried out by PSA, but 
also by hK2, and this leads to liquefaction 
of the seminal clot (Lilja 1985; Deperthes 
et al. 1996; Michael et al. 2006; Emami et 
al. 2008). This process is essential for the 
spermatozoa to gain proper motility and to 
fertilize the oocyte. 
 KLK1, -4 to -11 and -14 have been 
isolated from skin, and several possible 
functions have been suggested including 
degradation of desmosomes by KLK5, -7 
and -8, leading to desquamation (Kishibe 
et al. 2007; Lundwall & Brattsand 2008). 
Besides having functions in seminal 
fluid and skin, KLK4 is involved in the 
formation of teeth enamel (Simmer et al. 
1998). In the brain, KLK8, also known as 
neuropsin, degrades and rearranges extra-
cellular matrix (ECM) proteins and may 
play a role in synaptic plasticity associated 
with learning and memory (Shimizu et al. 
1998; Tamura et al. 2006). KLK6 and -8 
may also be involved in the pathogenesis 
of neurodegenerative disorders, such as 
Alzheimer’s disease, Parkinson’s disease 
and multiple sclerosis (Iwata et al. 2003; 
Terayama et al. 2007; Lundwall & Brattsand 
2008).
 One of the hallmarks of cancer 
is the increased expression/activity of 
proteases associated with matrix-degrad-
ing proteolytic pathways, contributing 
to the invasive properties of cancer cells 
(Hanahan & Weinberg 1999; Hanahan & 
Weinberg 2011). All KLKs except KLK12 
have been found to be differentially 
expressed in several cancers [reviewed in 
(Borgoño & Diamandis 2004; Paliouras & 
Diamandis 2006; Sardana et al. 2008)]. In 
prostate cancer, hK2, KLK4, -11, -14 and 
-15 have been found to be overexpressed 
and have been suggested to serve as tumor 
markers (Darson et al. 1997; Obiezu et 
al. 2002; Yousef et al. 2003; Paliouras et 
al. 2007). However, with the exception of 
hK2 the utility of these as tumor markers 
remains to be demonstrated. 
2.1. hK2 (human Kallikrein 2)
hK2 is a 28 kDa serine protease produced 
by prostatic epithelial cells and secreted 
into prostatic lumen and seminal fluid 
(Schedlich et al. 1987). Despite the high 
structural similarity with PSA, hK2 has a 
trypsin-like specificity with 20,000-fold 
higher enzymatic activity than PSA towards 
synthetic substrates in vitro (Mikolajczyk 
et al. 1997; Mikolajczyk et al. 1998). The 
proteolytic efficiency of hK2 against physi-
ological substrates varies widely (Clements 
et al. 2004). 
 Activation of proPSA by hK2 is 
probably physiologically important, since 
both proteases are produced by the prostate 
and secreted into seminal fluid. Thus, hK2 
may contribute to liquefaction of seminal 
clot by activating PSA and also by digesting 
semenogelins, although the proteolytic 
efficiency of hK2 towards semenogelins is 
much lower than that of PSA (Deperthes et 
al. 1996).
 When the architecture of prostate 
is disrupted, hK2, like PSA, leaks into 
circulation (Kwiatkowski et al. 1998). 
In prostate cancer, tissue expression of 
hK2 increases with increasing grade and 
high serum concentrations of hK2 are 
associated with poor prognosis (Darson 
et al. 1997; Lintula et al. 2005). Therefore, 
serum hK2 combined with serum PSA 
can improve diagnosis of prostate cancer 
(Saedi et al. 1998; Partin et al. 1999; Becker 
et al. 2000). Furthermore, measurement of 
serum hK2 can also help in discriminating 
organ confined from non-organ confined 
prostate cancer (Haese et al. 2000; Recker 
et al. 2000). In circulation, hK2 forms 
complexes with A2M, C1-inactivator, 
protein C inhibitor (PCI), α2-antiplasmin, 
plasminogen activator inhibitor 1 (PAI-1) 
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Figure 2. KLK activome and functions of active KLKs in tumorigenesis, skin desquamation, innate 
immunity, neurodegeneration, hypertension and semen liquefaction. Sotiropoulou et al. Functional 
Roles of Human Kallikrein-related Peptidases J Biol Chem 2009, 284(48), pp.32989-32994. © the 
American Society for Biochemistry and Molecular Biology. Reprinted with permission.
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and an unidentified serpin with a molecular 
weight of 63 KDa (Grauer et al. 1998; Heeb 
& España 1998; Mikolajczyk et al. 1998; 
Mikolajczyk et al. 1999b). In seminal 
plasma, the most abundant hK2 complex is 
that with PCI (Deperthes et al. 1995).
2.1.2. hK2 in Tumor Biology
Insulin-like growth factor-binding protein 
3 (IGFBP-3), a common substrate for hK2 
and PSA, is cleaved by hK2 with much 
higher potency than by PSA (Cohen et 
al. 1992; Réhault et al. 2001; Koistinen et 
al. 2002). Proteolysis of IGFBP-3 leads to 
increased bioavailability of IGF-I, which 
is the main ligand of IGFBP-3 (Jones & 
Clemmons 1995). IGF-I has promitotic 
and antiapoptotic effects in normal and 
differentiated cells (Bol et al. 1997). In 
the prostate it acts in a paracrine fashion 
(Meinbach & Lokeshwar 2006). IGF-I is 
produced by stromal cells and exerts its 
activity on epithelial cells carrying IGF-
receptors (Kaplan et al. 1999). IGFBP-3 
is expressed by prostatic epithelial cells 
(Chan et al. 1998). Increased IGF-I and 
decreased IGFBP-3 serum concentrations 
have been associated with an increased 
risk of developing prostate cancer in some 
(Chan et al. 1998), but not in all studies 
(Finne et al. 2000a; Chan et al. 2002). 
IGFBP-3 or its fragments also have IGF-in-
dependent effects on cell growth, i.e., they 
induce apoptosis and inhibit the growth of 
prostate cancer cell lines (Rajah et al. 1997; 
Boyle et al. 2001; Silha et al. 2006). 
 hK2, like KLK4, -5, -6 and -14, have 
been shown to activate protease activated 
receptors (PAR), thereby exerting direct 
stimulus on the cells (Oikonomopoulou 
et al. 2006). PARs are G-protein coupled 
transmembrane receptors, which are 
activated through proteolytic cleavage of 
the N-terminus of the extracellular domain 
of the protein (Vu et al. 1991; Coughlin 
1999; Coughlin 2000). In prostate cancer 
cells, hK2 activates PAR2 leading to phos-
phorylation and downstream activation 
of ERK1/2 signaling pathways and 
stimulation of cell proliferation (Mize et al. 
2008). PAR1, -2 and -4 are highly expressed 
in prostate cancer and benign tissue, and 
also in the prostate cancer cell line LNCaP 
(Black et al. 2007). 
 hK2 may act as a promotor of tumor 
invasion and metastasis by degrading 
components of ECM and by activating 
pathways related to the degradation of 
connective tissues (Clements et al. 2004; 
Lawrence et al. 2010). Another common 
physiological substrate of PSA and hK2 
is the ECM component fibronectin (Lilja 
1985). Like with IGFBP-3, hK2 cleaves 
fibronectin with much higher efficiency 
than PSA (Lövgren et al. 1999; Deperthes 
et al. 1996). hK2 activates urokinase-type 
plasminogen activator (uPA) (Frenette 
et al. 1997) and inactivates plasminogen 
activator inhibitor-1 (PAI-1) (Mikolajczyk 
et al. 1999a). As increased uPA activity is 
associated with prostate cancer (Achbarou 
et al. 1994; Lyon et al. 1995), these findings 
support the role of hK2 in extracellular 
proteolytic cascades in prostate cancer. 
Thus, hK2 may play an important role 
in prostate cancer growth and invasion 
(Figure 3) (Rittenhouse et al. 1998; 
Koistinen et al. 2008).
2.2. PSA (Prostate Specific Antigen)
PSA is a 28 kDa single chain serine protease 
with a restricted chymotrypsin-like 
substrate specificity, cleaving preferentially 
after tyrosine residues (Coombs et al. 1998). 
PSA is produced by prostatic epithelial cells 
and released into the lumen of the prostatic 
ducts as an essential component of seminal 
fluid (Wang et al. 1981). Its concentration 
in seminal plasma is 0.39-3 g/l (Wang et 
al. 1998). The main physiological function 
of PSA is to digest the major gel-forming 
proteins semenogelin-I and -II after 
ejaculation (Lilja 1985). In seminal fluid 
PSA occurs in at least 5 isoforms named 
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PSA-A to -E based on their order of elution 
in anion exchange chromatography (Zhang 
et al. 1995). Among these isoforms, PSA-A 
and -B have different isoelectric points 
due to differences in glycosylation, but 
have similar enzymatic activity, whereas 
PSA-C, -D and -E are partially degraded 
or “nicked” isoforms of PSA (Zhang et 
al. 1995; Mattsson et al. 2008). The major 
nicks in PSA occur between arginine-85 
and phenylalanine-86, lysine-145 and 
lysine-146, and lysine-182 and serine-183. 
(Watt et al. 1986; Lundwall & Lilja 1987; 
Zhang et al. 1995; Mattsson et al. 2008). 
The content of PSA forms cleaved after 
lysine-145 and lysine-182 are increased 
in BPH tissues and are therefore termed 
benign PSA (BPSA) (Mikolajczyk et al. 
2000). In seminal plasma, about 35% of 
PSA is cleaved (Zhang et al. 1995; Mattsson 
et al. 2008). The intact isoforms of PSA, 
i.e., PSA-A and -B, are fully active and 
form complexes with α1-antichymotrypsin 
(ACT), α1-protease inhibitor (API, also 
known as α1-antitrypsin, AAT) and A2M 
in vitro (Christensson et al. 1990; Chris-
tensson & Lilja 1994; Leinonen et al. 1996).
 From the normal prostate, only a 
minor part of PSA escapes into circulation. 
In prostatic diseases the barriers that 
prevent PSA leaking into circulation are 
disrupted, which results in elevation of the 
PSA concentration in blood (Stenman et 
al. 1999a). However, poorly differentiated 
prostate cancers produce less PSA than 
well differentiated ones (Abrahamsson et 
al. 1988; Stege et al. 2000; Paju et al. 2007). 
Thus, an increased PSA concentration in 
circulation is an indication of prostatic 
disease (Stamey et al. 1987; Armitage et 
al. 1988). As mentioned before, this makes 
PSA a very useful marker for prostate 
cancer, although a high serum PSA may 
also be caused by BPH and prostatitis 
(Stamey et al. 1987). Increased tumor 
volume correlates with PSA concentration 
in plasma (Stamey et al. 1987). In prostate 
cancer metastases, expression of PSA is 
generally maintained, but metastatic sites 
are heterogeneous and PSA expression 
varies (Stein et al. 1984; Roudier et al. 
2003).
2.2.1. PSA Complexes in Circulation
When enzymatically active PSA reaches 
circulation, it rapidly forms complexes 
with serine protease inhibitors (serpins) 
and A2M (Christensson et al. 1990; 
Stenman et al. 1991; Christensson & Lilja 
1994; España et al. 1996). In plasma 5-40% 
of the immunoreactive PSA occurs in free 
form, while 60-95% is in complex with 
ACT and a minor part with API. These 
PSA forms are detected by assays for total 
PSA (Stenman et al. 1991; Lilja et al. 1992; 
Zhang et al. 1997). In addition, 1-10% of 
PSA in plasma is complexed with A2M, 
which is not recognized by conventional 
immunoassays. It can be detected with PSA 
antibodies after denaturation by SDS or 
high pH (Zhang et al. 1998). As mentioned 
earlier, the proportion of free/total PSA 
(%fPSA) gives additional information for 
discriminating between BPH and prostate 
cancer (Stenman et al. 1991). 
2.2.2. PSA in Tumor Biology
Besides having a physiological role in re-
production, PSA may also be involved in 
tumor progression (Fortier et al. 1999; 
Clements et al. 2004; Koistinen et al. 2008). 
Like hK2, PSA degrades IGFBP-3 causing 
release of IGF-I, which may stimulate 
tumor development (Cohen et al. 1992; 
Sutkowski et al. 1999; Koistinen et al. 2002). 
PSA may play a role in the development of 
bone metastases by cleaving and inactivat-
ing parathyroid hormone related protein 
(PTHrP) (Cramer et al. 1996; Iwamura et 
al. 1996) and by promoting osteoblast pro-
liferation, inducing apoptosis in osteoclast 
precursors and promoting prostate cancer 
cell adhesion to bone marrow endothelial 
cells (Yonou et al. 2007; Goya et al. 2006; 
Romanov et al. 2004). PSA has been shown 
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to activate the latent form of the soluble 
transforming growth factor-β2 (TGF-β2), 
which has both tumor suppressor and 
promoter functions (Dallas et al. 2005; 
Killian et al. 1993). TGF-β activates cy-
toskeleton modulators, thereby rearranging 
cell cytoskeleton, inducing cell migration 
(Bhowmick et al. 2001), and causing loss 
of the epithelial phenotype via downregu-
lation of E-cadherin (Thiery 2002). Trans-
fection of non-PSA producing prostate 
cancer cell lines with PSA causes the cells 
to undergo epithelial to mesenchymal 
transformation (EMT) (Veveris-Lowe et 
al. 2005). This type of phenotypical change 
is generally associated with aggressive 
cancer (Thiery 2002). EMT-like processes 
include regulation of the cytoskeleton, 
cellular adhesion and migration (Thiery 
et al. 2009; Yilmaz & Christofori 2009). 
Other studies have shown that PSA may be 
associated with prostate cancer progression 
by degrading ECM components such as 
fibronectin and by activating matrix metal-
loproteinase 2 (MMP2) (Lilja 1985; Pezzato 
et al. 2004; Ishii et al. 2004; Webber et al. 
1995). PSA has also been found to cleave 
galectin-3 dimers and releasing functional-
ly active monovalent lectin, which may be 
involved in progression of prostate tumors 
(Saraswati et al. 2011).
 Inhibition of PSA expression by small 
interfering RNA (siRNA) has shown that 
PSA may promote growth of prostate cancer 
cells, via enhancing ARA70 induced AR 
transactivation, and increase subcutaneous 
growth of LNCaP prostate cancer cells in 
mice (Niu et al. 2008; Williams et al. 2011). 
Furthermore, transfection of enzymatically 
active PSA into a non-PSA producing cell 
line has been found to accelerate tumor 
growth (Williams et al. 2011). Ligation of 
prostate cancer cell surface GRP78 with 
PSA-A2M complex has been shown to 
activate a proliferative and antiapoptotic 
feedback loop that promotes tumor growth 
(Misra et al. 2011). 
 While the observations described 
above indicate a tumor promoting effect 
of PSA, other studies show that PSA 
actually inhibit tumor growth. When PSA 
is added to the culture medium, prostate 
cancer cell lines show various changes in 
their gene expression at the mRNA and 
protein levels (Bindukumar et al. 2005). 
Several of these differentially expressed 
genes are related to regulation of proan-
giogenic and antiangiogenic factors. This 
also showed that in vivo growth of prostate 
tumor xenografts is suppressed when PSA 
is injected in the vicinity of the tumor area. 
PSA exhibits antiangiogenic properties on 
endothelial cells in culture and in animal 
models (Fortier et al. 1999; Fortier et al. 
2003; Mattsson et al. 2009). This implies 
that PSA may act as an antiangiogenic 
agent in prostate cancer. Therefore, the 
slow growth of prostate cancer, at the stage 
when the tumor needs blood vessels, could 
be attributed to PSA. The antiangiogenic 
activity of PSA has been ascribed to the 
ability of PSA to generate angiostatin-
like fragments by cleaving plasminogen 
(Heidtmann et al. 1999). However, this has 
not been confirmed in other studies, and 
thus, other antiangiogenic mechanisms 
cannot be ruled out. Clinical observa-
tions suggest that PSA inhibits rather than 
promotes tumor growth. The expression of 
PSA is actually lower in malignant tissues 
than in the benign prostate (Abrahamsson 
et al. 1988; Paju et al. 2007). Tumors with 
high PSA expression have been associated 
with low microvessel density and antiangi-
ogenic activity (Papadopoulos et al. 2001; 
Ben Jemaa et al. 2010). Furthermore, low 
PSA concentrations in tumor tissue are 
associated with adverse outcome (Stege et 
al. 2000).
 The role of PSA in prostate cancer 
progression requires further elucidation. 
The studies cited above indicate that PSA 
may both stimulate and inhibit tumor 
growth (Figure 3). While this seems con-
troversial, it is conceivable that PSA in 
the early phase of development promotes 
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Figure 3. Possible roles for hK2 and PSA during tumor progression. 
tumor growth, but when the tumor reaches 
a size that it requires new blood vessels for 
further growth, PSA inhibits angiogenesis 
and thereby slows down tumor growth.
2.2.3. Potential Alternative Treatment 
Methods for Prostate Cancer Based on PSA
As mentioned earlier, PSA has been shown 
to exert both properties that may promote 
and inhibit tumor growth. Inhibition of 
PSA expression by shRNA in LNCaP cells 
reduced the growth rates of these cells 
and transfection of PSA into DU-145 cells 
increased cell proliferation (Williams et al. 
2011). This underlines the importance of 
the enzymatic activity of PSA. Treatment 
of PC-3M prostate cancer cell line with 
enzymatically active PSA results in up- 
and down-regulation of several proteins 
(Bindukumar et al. 2008), some of which 
are related to prostate cancer progression. 
Most significant changes like upregula-
tion of laminin receptor (Ménard et al. 
1998), DJ-1 (Tillman et al. 2007) and Glyc-
eraldehyde 3-phosphate dehydrogenase 
(GAPDH) (Rondinelli et al. 1997) have 
been shown to favor tumor inhibition. In 
another study, PSA has been shown, at 
concentrations found in a healthy prostate 
gland, indirectly to enhance natural killer 
(NK) cells to secrete interferon-γ, which 
has antitumor and immunoregulatory 
activities (Fang et al. 2008). Antiangio-
genic property of PSA is suggested to be 
mediated by its ability to generate active 
angiostatin fragments from lys-plasmi-
nogen (Heidtmann et al. 1999). These 
recent findings of PSA suggesting a role in 
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maintaining homeostasis in the prostate 
cancer indicate that downregulation of 
PSA expression may act on predisposition 
of the prostate tissue to the development 
of cancer and it may be linked to a more 
aggressive disease. PSA may exert some 
of its antitumor effects via enzymatic 
activity, such as angiostatin generation, 
however, some of its actions may not 
require its enzymatic activity (Bindukumar 
et al. 2005). Considering that decreased 
amounts of PSA in prostate tumor tissue is 
associated with poorly differentiated cells 
and late stages of malignancy (Stege et al. 
2000), it may be feasible to maintain PSA 
activity for treatment of prostate cancer. 
Furthermore, enhancing the PSA activity 
may even be more beneficial to regain 
the physiological homeostasis within the 
prostate tissue. Recently PSA-specific 
binding peptides have been identified by 
phage display library screening, which 
enhance the enzymatic activity of PSA 
(Wu et al. 2000). These peptides, as they 
are or their peptidomimetic derivatives, 
are potential drugs for prostate cancer. 
As these peptides specifically target PSA, 
they also have potential use for imaging 
of prostate cancer metastases. This may 
improve prostate cancer diagnosis by 
providing more information on the 
progress of prostate tumor growth. 
 Another alternative approach for 
treatment of prostate cancer is utilizing 
cytotoxic agents, such as doxorubicin or 
thapsigargin prodrugs, coupled to PSA 
substrates so that they are activated in the 
vicinity of prostate tumor where the PSA 
concentration is highest (DeFeo-Jones et 
al. 2000; Denmeade et al. 2003). This type 
of therapeutical method could reduce 
the side effects of a cytotoxic drug as it is 
engineered to be tumor tissue specific.
3. Prostate Cancer Models
In cancer research, in vitro and in vivo 
studies are carried out with various models 
that try to recapitulate the characteristics 
of the particular cancer type of interest. 
For prostate cancer these include various 
cell lines, some of which form xenograft 
tumors when introduced in animals, 
transgenic animal models, genetically 
engineered models and spontaneously 
tumor forming animals.
 Most commonly used prostate cancer 
cell lines in the literature are DU-145 (Stone 
et al. 1978), PC-3 (Kaighn et al. 1979) and 
LNCaP (Horoszewicz et al. 1983), which 
were established from bone, brain and 
lymph node metastases of human prostatic 
adenocarcinoma, respectively. LNCaP 
cells express mutant AR (Veldscholte 
et al. 1990), whereas PC-3 and DU-145 
express very little or none (Sobel & Sadar 
2005). The proliferation of LNCaP cells 
can be stimulated by treating them with 
androgens (Horoszewicz et al. 1983), and 
due its mutant AR also with several steroid 
hormones and anti-androgens (Veldscholte 
et al. 1992). Androgen treatment of LNCaP 
cells also increases the production of PSA 
and hK2 (Montgomery et al. 1992; Young et 
al. 1992; Grauer et al. 1996). As most of the 
prostate cancer cell lines express either very 
little or no AR, LNCaP is perhaps the most 
relevant cell line for studying the biology 
of early prostate cancer. Late stage tumors 
generally develop androgen resistance as 
a response to hormone therapy (Koivisto 
et al. 1998). In this respect, progression 
of prostate cancer development has been 
mimicked by coinoculating LNCaP cells 
with non-tumorigenic MS fibroblasts into 
athymic nude mice and in vivo passaging 
several sublines (Thalmann et al. 1994; 
Hyytinen et al. 1997). By maintaining the 
LNCaP tumors in castrated mice, also an-
drogen-independent LNCaP sublines have 
been established (Thalmann et al. 1994). 
Another androgen-dependent prostate 
cancer cell line that expresses PSA is 22RV1 
(Sramkoski et al. 1999). The cell line has 
been established by in vitro propagation 
from a xenograft model for primary 
human prostate carcinoma CWR22, 
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which represents relapsed primary cancer 
(Wainstein et al. 1994; Sramkoski et al. 
1999). Another cell line derived from 
the same xenograft tumors is CWR22Pc, 
which grows androgen dependently and 
expresses high levels of PSA (Dagvadorj et 
al. 2008). When injected subcutaneously 
into nude mice, CWR22Pc grows androgen 
dependently and releases PSA into 
circulation. The PSA levels in the serum 
of this model were shown to correlate 
with tumor volume. In addition, MDA 
PCa 2a and -b cell lines, established from 
bone metastasis of a patient with advanced 
prostate cancer, are androgen sensitive, and 
produce hK2 and PSA (Navone et al. 1997; 
Lawrence et al. 2010). Also VCaP cells, 
derived from vertebral metastatic lesions, 
express large quantities of PSA (Korenchuk 
et al. 2001).
 Subcutaneous or orthotopical 
xenograft tumor models for prostate cancer 
are either derived from in vitro cultured cells 
like those mentioned above (van Weerden 
& Romijn 2000; Sobel & Sadar 2005) or 
propagated in vivo such as CWR22, PC-82, 
LAPC-4 and -9, and LuCaP23 (Craft et 
al. 1999; Klein et al. 1997; Ellis et al. 1996; 
Hoehn et al. 1980; van Weerden & Romijn 
2000). Most commonly used mice strain 
for this purpose is nude mice (Foxn1nu), 
which have a reduced immune system due 
to defect in development of thymus gland 
(Flanagan 1966; Pantelouris 1968; Segre 
et al. 1995; Kaestner et al. 2000). LNCaP 
xenograft tumors can be established by 
injecting the cells together with basement 
matrix support under the skin of nude mice 
(Papsidero et al. 1981; Lim et al. 1993). 
 For studies of certain pathways or 
oncogenes in prostate cancer development, 
transgenic mouse models have been 
established. The main strategy is to 
manipulate the target genes for gain- or 
loss-of-function. Transgenic adenocar-
cinoma of the mouse prostate (TRAMP) 
is a mouse model developed using rat 
probasin promoter to express the SV40 
early gene (T/t antigen:Tag), which was 
targeted to the differentiated columnar 
epithelial cells of the mouse prostate 
(Greenberg et al. 1994). This model mimics 
human disease histologically and patho-
logically with metastatic spread to distant 
sites. Transgenic Lady model, which is 
developed using prostate-specific probasin 
promoter, is less aggressive reflecting the 
early stages of prostate cancer. Also PSA 
and hK2 transgenic mouse have been 
described (Williams et al. 2010; Zhang 
et al. 2000). However, the levels of PSA 
produced by this transgenic model were 
found to be 1000-fold lower than in human 
prostate and PSA was not detectable in the 
serum of these models. 
 Another strategy to mimic the natural 
initiation and progression of cancer is 
to use mouse prostate reconstitution 
model (Thompson 1996). In this model, 
by introducing the ras and myc, or both 
oncogenes in recombinant retrovirus, 
different phenotypes of prostatic pathology 
can be established, like dysplasia, 
hyperplasia and frank carcinomas, respec-
tively (Thompson et al. 1991). Spontaneous 
prostate tumors develop in some strains 
of rats, such as, the Dunning R-3327, 
Lobund Wistar and ACI/Seg (Pollard 1998; 
Dunning 1963). Spontaneous prostate ad-
enocarcinoma occurs most commonly 
in dogs resembling closely to the human 
disease (Lamb & Zhang 2005).
 Most of the cell lines suitable for 
prostate cancer studies are derived from 
metastatic lesions and unfortunately, do 
not mimic early stages of prostate cancer 
development very well (Peehl 2005). 
Primary cultures of prostate cancer and 
their gene expression profile comparison 
to healthy prostate tissue provide useful 
tools for prostate cancer research (Peehl 
2005). However, several challenges remain 
including isolation and characterization of 
these cultures with diverse genomic profile. 
Coordinated collection for large number 
of fresh prostate tumor tissues focused 
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on primary cultures of prostate cancer 
is possible by biobanking (Dhir 2008). 
Similar as it is with the in vitro culture 
of the cell lines, prostate tumor animal 
models currently in use can recapitulate 
certain aspects of the disease, but none of 
these can truly represent the complexity of 
human prostate cancer.
4. Peptides as Drugs
Peptides are 3 to 50 amino acid long 
single chained amino acid polymers 
connected by peptide bonds (Jones 2006). 
In biological systems, peptides have several 
roles such as acting as hormones, growth 
factors and neurotransmitters. Most of the 
naturally occurring regulatory peptides 
exert their activities by binding to specific 
target proteins or receptors, and activate or 
inhibit downstream pathways that regulate 
biological processes of cells including 
proliferation and apoptosis (Reubi 2003). 
Analogues of these naturally occurring 
peptides and active domains of proteins 
can be chemically synthesized to develop 
peptide drugs (Watt 2006). Bioactive 
peptides, that are native for the human 
body, are mostly highly stable in vivo 
and not immunogenic (Sato et al. 2006). 
Many bioactive peptides are already in 
use as drugs. These include insulin to treat 
diabetes, adrenocorticotropic hormone 
(ACTH) to treat secondary adrenal in-
sufficiency, oxytocin for inducing labor, 
ghrelin to treat obesity, and glucagon-
like peptide 1 (GLP-1) for the control of 
diabetes (Dhillo & Bloom 2001). Another 
approach to peptide drug development is 
discovery of novel peptides by scanning 
peptide libraries against proteins. These 
libraries can be generated chemically 
or genetically (Latham 1999; Landon et 
al. 2004; Laakkonen & Vuorinen 2010). 
For example, by using phage display 
libraries peptide inhibitors for proteases, 
such as gelatinases, have been developed 
(Koivunen et al. 1999). 
 Currently, a majority of drugs in 
clinical use are small molecule compounds 
that have favorable pharmaceutical 
properties such as small size, straightfor-
ward synthesis, low price, oral availability 
and ability to cross biological membranes 
(Lipinski et al. 2001). As drugs, peptides 
have several disadvantages over these 
traditional small molecule drugs such 
as larger size, poor in vivo stability, fast 
clearance from circulation, and their 
production can be challenging and costly. 
Despite their drawbacks, peptides have 
unique properties that may be beneficial 
(Table 2). Peptides can bind to their 
targets with higher affinity and specificity. 
Furthermore, they can be used to target 
mechanisms that small molecules cannot 
(Sato et al. 2006). Peptides are mostly 
non-toxic, have low immunogenicity and 
do not accumulate in the internal organs like 
liver or kidney. Peptides can be chemically 
synthesized in mass amounts with high 
yield and purity, although production in 
large quantities can be expensive. Peptides 
are also considered to be alternative to 
antibody-based drugs that have high 
affinity and specificity (Ladner et al. 2004). 
Although antibodies are highly stable in 
circulation and mostly non-immunogenic, 
low tissue penetration properties makes 
them less suitable for treatment of solid 
tumors. Compared to antibodies, peptides 
have higher activity per mass. Manufac-
turing of peptides is usually cheaper than 
that of antibodies and they are more stable 
during long time storage (Ladner et al. 
2004). Monoclonal antibodies (Mabs) have 
been used in treatment of cancer (Mehren 
et al. 2003). Anti-HER2 targeting Mabs 
are used as a therapy for metastatic breast 
cancer that overexpresses HER2 (Le et al. 
2005). Rituximab, a monoclonal antibody 
that targets B-lymphocyte antigen CD20 
and stimulates cytotoxic mechanisms, has 
been used for treatment of non-Hodg-
kins lymphoma and chronic lymphocytic 
lymphoma (CLL) (Mavromatis & Cheson 
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2003; Plosker & Figgitt 2003). However, 
most of the patients treated with rituximab 
experience infusion-related or hemato-
logical adverse effects (Plosker & Figgitt 
2003). Introducing non-human Mabs into 
human body also can trigger immunogenic 
reactions towards these Mabs (White et al. 
2001). Furthermore, accumulation of Mabs 
in kidneys and liver may cause damage 
to these organs (Abdel-Nabi et al. 1992). 
These problems with Mab treatment can 
be partially overcome by converting the 
Mabs to a single chain Fv domain, which 
is the active part of the antibody (White 
et al. 2001; Mehren et al. 2003). Recently, 
peptibody technology, which fuses the 
highly stable Fc part of an antibody with 
a peptide, has been emerging (Wang et al. 
2004). Peptibody, peptide-antibody hybrid, 
combines high stability of antibodies 
with powerful ligand selection for targets 
property of peptide libraries (Molineux & 
Newland 2010). Romiplostim, a peptibody 
that mimics thrombopoietin (TPO) and 
acts as TPO receptor agonist, has been used 
to treat immune thrombocytopenia (ITP), 
an autoimmune disorder characterized by 
decreased number of circulating platelets.
 In 2010, over 60 therapeutic peptide 
drugs were on market and many more were 
under development (Vlieghe et al. 2010). An 
example of recently approved peptide drug 
is enfuvirtide (Fuzeon, T-20), a 36-amino 
acid long therapeutic peptide that is used 
to treat HIV-1 infection (Matthews et al. 
2004). The peptide is a replicate of residues 
127-162 of the transmembrane viral gly-
coprotein gp41 (Wild et al. 1994), which 
inhibits the fusion of viral and plasma 
membranes, thereby preventing entry of 
the virus into host cells (Kilby et al. 1998). 
The recommended dosage for adults is 
90 mg per day, which is a large amount 
considering the production costs (Fung & 
Guo 2004). Despite the high production 
price, which is due to the complexity of 
the peptide, the unique properties of this 
peptide makes it a most effective treatment 
method for HIV-1 infection (Badia et al. 
2007).
 Besides being therapeutic tools, 
certain peptides have the ability to 
penetrate into cell cytoplasm by transloca-
tion accross cell membranes (Wagstaff & 
Jans 2006). These peptides can be linked 
to “cargo” molecules for intracellular 
delivery, which makes them efficient drug-
carrier molecules for targeting cytoplasmic 
pathways. 
 Although peptide drugs mostly have 
some disadvantages such as low oral bio-
availability and tendency for quick me-
tabolization, the interest of pharmaceu-
tical companies in therapeutic peptides 
is increasing. This is mostly because of 
few side effects, high specificity and easy 
mimicry of peptides or proteins that are 
part of physiological mechanisms.
Table 2: Advantages and challenges of peptides as drugs
Advantages Challenges
High	specificity Low oral bioavailability
High activity Strenuous	delivery	(injection)
Little	non-specific	binding	to	molecular	
structures other than desired target
Poor transportation across membranes
Minimization of drug-drug interactions Challenging & costly synthesis
Low toxicity Solubility
Often very potent Risk of immunological effects
Biological & chemical diversity for target Rapid clearance from body
Modified and adapted from Vivien 2005 Chem Eng News 83(11), pp.17-24
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4.1. Phage Display Libraries and Peptides
One commonly used method to identify 
novel ligands for target proteins is phage 
display technology (Smith 1985; Smith 
& Petrenko 1997). The method is based 
on random expression of peptides with 
predefined structures as part of the coating 
proteins on the phage (Scott & Smith 1990). 
Collections of phage that are engineered to 
express these certain predefined structures 
with random amino acid sequence are 
called phage libraries (Smith 1985). Phage 
display is mainly used for identification of 
peptides or antibody recognition sites, but 
it can also be applied to epitope discovery 
and mimicry, and substrate identifica-
tion for enzymes (Smith & Petrenko 
1997; Ruoslahti & Rajotte 2000; Cloutier 
et al. 2002). Peptides conjugated to the 
phage coating protein generally have fixed 
number of amino acids and may have fixed 
positions for certain amino acids (Scott & 
Smith 1990). Based on their ability to form 
disulphide bridges, cysteine residues can 
be used to create variations in the tertiary 
structures. Most of the ligands found by 
phage display have high specificity towards 
the target (Parmley & Smith 1988). 
When applied for enzymes, it is possible 
to identify peptides that modulate their 
enzymatic activity (Koivunen et al. 1999).
 In screening, a phage library 
is incubated with the target protein 
followed by selection and enrichment 
of bound phage (Smith 1985). After 
several successive rounds of selection and 
enrichment (Figure 4), the DNA of the 
phage is sequenced to identify the peptide 
ligand (Sidhu et al. 2000). After the iden-
tification of the peptide for the target, it 
can be synthesized chemically. If the target 
is an enzyme, the effect of the peptide on 
the enzymatic activity can be studied, 
as binding may modulate, i.e., inhibit or 
enhance the activity. Characterization of the 
peptides can be carried out by determining 
the amino acids necessary for the binding 
or for the modulatory effect. This can be 
achieved by performing step-by-step single 
modifications of the peptides, such as 
alanine scanning, deletion of the residues 
and trimming from C- and N- termini. 
 Other methods to screen and identify 
ligands for target receptors or proteins 
include peptide arrays (Frank 2002), 
peptide bead libraries (Lowe 1994) and 
positional scanning of synthetic combi-
natorial libraries (PS-SCL) (Barrios & 
Craik 2002; Rubio-Godoy et al. 2002), all 
of which uses solid-phase combinatorial 
chemistry to generate diversity.
4.2. Modification of the Peptides for 
Improved Stability
When developing therapeutic peptides, 
probably the biggest challenge is their poor 
stability. After oral administration they 
are rapidly degraded by the enzymes in 
gastrointestinal tract (Veber et al. 2002). 
Therefore, peptides need to be delivered 
by alternative routes, such as subcutane-
ous (s.c.) or intravenous (i.v.) injection 
(Weber et al. 1992). However, after i.v. 
injection peptides may also be degraded 
by peptidases in the circulation (Witt et 
al. 2001). And even if they withstand the 
proteolytic attack, they are often excreted 
via kidneys into urine because of their 
small size.
 Blood contains several active exo-
peptidases which proteolyze peptides from 
N- or C- termini. Therefore, especially 
open-ended linear peptides are often 
vulnerable in circulation and rapidly 
degraded into single amino acids by exo-
peptidases. Addition of one or several 
polyethylene glycol (PEG) groups to 
the N- or C- termini or both ends of the 
peptides prevents peptides being degraded 
by the exopeptidases (Harris & Chess 
2003). Conjugation of PEG, termed as 
PEGylation, to peptides may change the 
charge of the peptide resulting in improved 
solubility and activity, but it may also 
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A library of phage displaying random 
peptide sequences on their pIII coat 
protein, is exposed to a target 
antibody captured protein in micro-
titer wells.
Unbound phage are 
washed away
Specifically-bound 
phage are eluted
After 3 to 4 rounds, individual 
clones are isolated and their DNA 
sequenced for the identification of 
the peptide
Specifically-bound 
phage are amplified 
by infecting host cells
Panning and selection 
steps are repeated 3 or 
4 times
result in loss of function. PEGylation of a 
peptide increases its size according to the 
number of added residues. This reduces 
clearance from circulation via kidneys, 
thereby prolonging its half-life (Veronese 
& Pasut 2005). Similarly, peptides can 
be conjugated to albumin, which as well 
prevents excretion via kidneys. Also as 
mentioned earlier, coupling peptides to Fc 
parts of antibodies is an efficient method to 
increase the half-life of peptides (Wang et 
al. 2004).
Figure 4. Short schematic description of phage display method for identification of peptide ligands 
against proteins that are captured by an antibody. 
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 Another method to prevent exo-
peptidase degradation and to improve the 
stability is cyclization. Linear peptides 
can be cyclized either by adding cysteine 
residues to both ends to form disulphide 
bonds or simply by engineering a peptide 
bond from head-to-tail (Adessi & Soto 
2002; Clark et al. 2005). However, 
cyclization of a bioactive peptide may 
impair its functions.
 Cyclization and PEGylation may 
prevent degradation by exopeptidases, 
but not by another class of peptidases 
called endopeptidases that cleave peptide 
bonds within the peptide. Contrary to 
exopeptidases, most endopeptidases in 
circulation are inhibited by serpins, A2M 
and other protease inhibitors (Huntington 
2003). However, active endopeptidas-
es are abundant in the small intestines 
making oral administration challenging 
for therapeutic peptides. Also the targeted 
tissues may contain endopeptidases.
 Several other strategies can be used 
to improve the stability of peptides. These 
include modification of the chemical 
structure of the peptide, engineering of 
pseudopeptides and peptidomimetics 
(Adessi & Soto 2002). Modifications of 
the chemical structure of peptides include 
synthesis of the peptides as D-isomers with 
reversed amino acid sequence (Milton 
et al. 1992; Guichard et al. 1994), N- or 
C- termini modifications, replacement of 
natural amino acids with non-coded amino 
acids and alkylation of N-amide nitrogen 
(Heavner et al. 1986). Pseudopeptides can 
be made by replacement or alteration of 
atoms that are part of the peptide backbone 
(Benovitz & Spatola 1985). These include 
amide bond surrogates, translation of 
the peptides into peptoids or β-peptides, 
both of which are based on modified 
amino acids with side-chain substitu-
ents (Zuckermann et al. 1992; Seebach et 
al. 1996), and conversion to azapeptides 
or azatides, where one or more α-carbon 
atoms are replaced by nitrogen atoms 
(Magrath 1992). Peptidomimetics, where 
peptides are mimicked by using chemical 
methods, may be another efficient way of 
combining the desired properties of both 
peptides and chemical compounds (Perez 
et al. 2002). By definition (IUPAC, In-
ternational Union of Pure and Applied 
Chemistry) peptidomimetics do not have 
classical peptide characteristics such as en-
zymatically scissile peptide bonds. Peptides 
provide promising molecular scaffolds for 
drug discovery, i.e, they can serve as lead 
molecules in drug discovery (Mergener 
1998). This way, peptide traits such as high 
specificity and potency could be combined 
with drug properties, which are cheap 
production, oral administration and high 
stability (Lipinski et al. 2001; Hummel et 
al. 2006).
 Peptidomimetics or conversion to 
small drug compounds may significant-
ly reduce production costs and increase 
stability in the digestive tract so that they 
could be administered orally. However, as 
for peptides, rather quick degradation and 
renal clearance are not always undesirable 
properties as short half-life of peptides 
may make them less toxic and easily 
manageable. After their task is complete, 
disappearance of the peptides may ease the 
burden on the liver and decrease potential 
side effects due to tissue accumulation. As 
a drug, the ideal peptide would be stable 
enough to penetrate the target tissue, 
but then be cleared from the system in a 
suitable time period.
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hK2 and PSA are nearly exclusively produced by the healthy human prostate and by 
prostate tumors, which makes these proteases potential targets for prostate cancer therapy. 
This work aims to find hK2-specific novel peptide ligands that can be used to study the 
role of hK2 in prostate tumors and as lead molecules for development of peptide-based 
drugs for prostate cancer treatment. It also intends to further characterize the behavior of 
PSA in animal models. 
The main goals in this study are
I. To identify and characterize specific peptides modulating the activity of hK2.
II. To improve the stability of hK2-inhibiting peptides for in vivo studies. 
III. To study the inhibition of hK2 activity towards cancer-related substrates by hK2-
inhibiting peptides.
IV. To characterize PSA complexes in mouse serum.
Aims of the Study
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1. Proteases, Substrates and Antibodies
The proteases, substrates and antibodies 
used are described in Table 3.
2. Immunofluorometric Assays (IFMAs)
2.1. IFMA for Free and Total PSA
Free and total PSA were quantified simulta-
neously using a dual-label IFMA (DELFIA 
Prostatus free/total PSA kit, Perkin-Elmer, 
Turku, Finland) according to the manu-
facturer’s instructions. The assay for total 
PSA recognizes PSA-ACT and PSA-API, 
but not PSA-A2M complexes (Zhang et al. 
1998).
2.2. IFMA for Intact and Total IGFBP-3
To measure concentrations of intact and 
total IGFBP-3 we have used two in-house 
built assays (Koistinen et al. 1994; Koistinen 
et al. 2002). For the intact IGFBP-3 assay, 25 
µl of standards and samples were pipetted 
into the 1B6 antibody coated wells followed 
by addition of 200 µl assay buffer (AB) [TBS 
(0.05 M Tris buffer, pH 7.7, containing 
0.154 M NaCl and 8 mM NaN3) containing 
2.3 g/l bovine serum albumin and 0.15 
g/l bovine globulin]. After overnight 
incubation at +4 °C wells were washed and 
europium-labeled tracer antibody 5C11 in 
DTPA containing AB was added for 1 h 
incubation at room temperature followed 
by another washing step. Enhancement 
solution (PerkinElmer Life Sciences) in 
200 µl volume was added and incubated 5 
min. Then fluorescence was measured with 
a Victor 1420 fluorometer (PerkinElmer 
Life Sciences) in time-resolved mode. To 
detect total IGFBP-3, i.e., both cleaved 
and intact proteins, similar protocol was 
followed except the catcher antibody was 
5C11 and the tracer 7F8. 
2.3. IFMA for Phage expressing 
hK2-binding Peptides
The phage IFMA was performed essentially 
as described (Wu et al. 2000). The solid 
phase antibody (5E4) was coated onto mi-
crotitration wells at a concentration of 5 
mg/l in TBS for 16 h at 22 °C, the solution 
was discarded, and the wells were saturated 
with 10 g/l BSA in TBS for 3h at 22 °C. 
In the assay 50 ng of hK2 in 200 µl of AB 
was captured onto wells coated with mAb 
5E4. Following a 1 h incubation the wells 
were washed and 2.5 µl of phage (108-109 
infectious particles) in 200 µl of AB was 
added. After incubation for another hour, 
the wells were washed and filled with 200 
µl AB containing 100 ng of europium-
labeled (Hemmilä et al. 1984) polyclonal 
anti-phage antibody recognizing the M13 
coat protein of the phage. After incubation 
for 1 h the wells were washed and 
enhancement solution was added. The flu-
orescence was measured with a Victor 1420 
fluorometer (PerkinElmer Life Sciences) in 
time-resolved mode.
2.4. Cross-Inhibition Tests
The relative binding sites of the peptides 
on hK2 were mapped by competition 
experiments. The protocol was based on the 
IFMA method described above, except that 
various cloned phage and various synthetic 
peptides were reacted together with hK2. 
Briefly, each of the synthetic peptides at 
a concentration of 5 µM was added into 
wells in which hK2 had been captured by 
mAb 5E4. After incubation for 30 min, 
hK2-binding peptide expressing phage 
(1010-1011 units) were added, and after 1 
h incubation the wells were washed, and 
bound phage were detected as described 
above for phage IFMA.
Materials and Methods
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Table 3: Proteases, substrates and antibodies used in this study. 
Protease Remarks Study Source
Enzymatically active PSA 
(PSA-B)
purified	from	human	seminal	plasma I, III
Zhang et al. 1995, Wu et 
al. 2004
proPSA
purified	from	LNCaP	cell	culture	
medium
I Wu et al. 2004
hK2 recombinant produced in insect cells I, III, IV Lövgren et al. 1999
IGFBP-3 recombinant human III Peprotech	(London,	UK)
Bovine trypsin, 
α-chymotrypsin I
Athens Research and 
Technology	(Athens,	GA)
Human plasmin, 
thrombin,plasma kallikrein
I Sigma-Aldrich
Trypsin 1, 2, 3 and C produced in-house I Koistinen et al. 2009
Substrate Protease specificity 
(sequence)
Study Source
Chromogenic substrates
S-2586
PSA and chymotrypsin
(MeO-Suc-Arg-Pro-Tyr-pNA)
I
Chromogenix In. Lab. 
(Milano,	Italy)
S-2222
Trypsin
(CO-Ile-Glu-(OR)-	Gly-Arg-pNA)
I Chromogenix In. Lab.
S-2238
Thrombin
(H-D-Phe-pipecolic	acid-Arg-pNA)
I Chromogenix In. Lab. 
S-2403
Plasmin 
(pyroGlu-Phe-Lys-pNA)
I Chromogenix In. Lab.
S-2302
hK2 and plasma kallikrein
(H-D-Pro-Phe-Arg-pNA)
I, II Chromogenix In. Lab.
Fluorogenic substrates
Fluorogenic	PSA	substrate	(4-morpholinecarbonyl-	HSSKLQ-
amidomethylcoumarin)	based	on	Denmeade	et	al.	1997
III
JPT Peptide Technologies 
(Berlin,	Germany)
Antibody Description Study Source
5E4
anti-PSA and -hK2 monoclonal 
antibody
I, IV Leinonen et al. 2002
ab6188 anti-M13 bacteriophage coat protein I Abcam	(Cambridge,	UK)
5C11, 1B6, 7F8 anti-IGFBP-3 monoclonal antibodies III Koistinen et al. 1994
P0260 rabbit anti-mouse IgG III Dako, Glostrup, Denmark
A0562 rabbit anti-PSA polyclonal antibody IV Dako
P0217
swine anti-rabbit polyclonal IgG 
conjugated with HRP
IV Dako
J1105	(Vectastain) control rabbit IgG IV
Vector Labs, Burlingame, 
CA 
I5381 non-specific	mouse	antibody IV Sigma-Aldrich
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3. Determination of Enzymatic Activity
3.1. hK2
hK2 (0.17 µM) was incubated with a 100 
–1000-fold molar excess of hK2-specific 
synthetic peptides in 20 mM Tris buffer, 
pH 8.0, containing 1 g/l BSA, for 30 min 
at room temperature. After addition of 
the S-2302 substrate to a final concentra-
tion of 0.2 mM, the absorbance at 405 nm 
was monitored at 5-10 min intervals for 1 h 
with a Victor 1420 Multilabel fluorometer. 
Student’s t test was used to evaluate the 
significance of the hK2 inhibition by the 
peptides.
3.2. Other Serine Proteases
The specificity of the peptides was 
analyzed by studying their effect on the 
activity of other serine proteases including 
α-chymotrypsin, bovine trypsin, human 
trypsin 1, 2, 3, and C, urokinase, thrombin, 
plasmin, plasma kallikrein, and PSA. All 
of the substrates for these serine proteases 
were chromogenic (see table 3). The con-
centrations suggested by the manufac-
turer were used. As in hK2 enzymatic 
activity measurement, the activities of the 
proteases were monitored with a Victor 
1420 Multilabel fluorometer at 405 nm 
absorbance in 5-10 min intervals. 
4. hK2 Inhibition Towards Natural 
Substrates
4.1. Inhibition of hK2-Mediated Activation 
of proPSA by Peptides
hK2 is known to activate proPSA (Lövgren 
et al. 1997). To determine whether the 
peptides are able to inhibit this activity, the 
hK2-binding peptides, hK2p01, hK2p02, 
and hK2p03, were incubated with hK2 for 
50 min at room temperature in TBS buffer 
containing 1 g/l BSA before the addition of 
proPSA. Concentrations of peptides, hK2, 
and proPSA were 0-100 µM, 7.5 nM, and 
150 nM, respectively, in a final volume of 
50 µl. After incubation for 2 h, 10 µl of 2.4 
mM fluorogenic PSA substrate was added. 
Fluorescence (excitation at 355 nm and 
emission at 460 nm) was measured after 
17.5 h of incubation in a Victor 1420.
4.2. Inhibition of hK2-Mediated 
Degradation of IGFBP-3 by Peptides 
hK2 (5 nM final concentration) was 
preincubated with hK2-inhibiting peptides 
hK2p01, hK2p01b, hK2p02 and hK2p03 
(1, 10 and 100 µM) for 30 min at room 
temperature in TBS buffer containing 1 g/l 
BSA before addition of IGFBP-3 (1.5 nM 
final concentration). After incubation for 
24 h at 37 °C, the concentrations of IGFBP-3 
were measured using two sandwich-
type immunofluorometric assays, one 
recognizing only intact IGFBP-3 and the 
other both cleaved and intact (i.e., total) 
IGFBP-3 (section 2.2). 
5. Enzyme Kinetics Measurements of 
hK2 Inhibition by Peptides
The inhibitory capacity of the peptides 
was characterized by determining IC50 
value for hK2 inhibition on the basis of 
the velocity of S-2302 cleavage at 200 
µM concentration by 0.17 µM hK2 in the 
presence of 0-400 µM peptide. In addition, 
the Ki value for the most potent inhibitory 
peptide was determined by a Lineweaver-
Burk plot after determining the velocity of 
the cleavage of 0-400 µM S-2302 substrate 
by 0.2 µM hK2 in the presence of 4 µM of 
peptide. Ki values were also determined for 
peptides inhibiting hK2 towards IGFBP-3. 
hK2 (5 nM final concentration) was pre-
incubated with hK2-inhibiting peptides 
hK2p01, hK2p01b, hK2p02 and hK2p03 
(1, 10 and 100 µM) for 30 min at room 
temperature in TBS buffer containing 1 
g/l BSA before addition of IGFBP-3 (1.5 
nM final concentration). The final volume 
in the 96-well microtiter wells was 120 
µl. After incubation for 24 h at 37 °C, the 
concentrations of intact and total IGFBP-3 
were measured using sandwich-type im-
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munofluorometric assays (section 2.2). Ki 
values were determined using 0.2 nM hK2, 
3-50 nM IGFBP-3 and 0-10 µM peptides 
and the SigmaPlot 11.1 program with 
Enzyme Kinetics Module 1.3 (both from 
Systat Software Inc., San Jose, CA, USA).
6. Phage Display Library Screening
Construction of the phage display libraries, 
CX7C, CX8C, X9, X10, X11, CX3CX3CX3C 
(C=cysteine, X=any of the 20 randomly 
occurring natural amino acids) in fUSE-5-
phage and screening of these libraries were 
done as previously described (Koivunen 
et al. 1994b; Koivunen et al. 1994a). Each 
peptide library was screened against hK2, 
which was captured by 5E4 coated onto 
microtiter wells (Wu et al. 2000). mAb 
5E4 binds PSA and hK2 in an equimolar 
manner and reacts with an epitope, which 
is remote from the active site of these 
enzymes (Leinonen et al. 2002; Stenman 
et al. 1999b). hK2 in the amount of 24 ng 
was incubated in antibody-coated wells for 
30 min at 37 °C in 100 µl of TBS followed 
by washing with TBS to remove unbound 
hK2. An aliquot of each phage library 
containing 1010-1011 transducing units was 
added into the microtiter wells in 100 µl 
of TBS containing 10 g/l BSA. Incubation 
took place at 4 °C with gentle shaking for 
16-24 h in the first round and for 1 h for 
the following three rounds. The wells were 
washed 10 times with TBS containing 0.5% 
Tween 20. To elute bound phages, 100 µl 
of 0.1 M glycine-HCl, pH 2.2, containing 
1 g/l BSA was added. The eluted phage 
suspension was neutralized with 1 M Tris 
buffer, pH 9.0, amplified by infection of 
kanamycin-resistant Escherichia coli K91 
cells and purified by polyethylene glycol 
precipitation (Wu et al. 2000). After four 
rounds of selection and amplification, 
single-stranded DNA from individual 
phage clones was prepared. The relevant 
part of the viral DNA, after amplification by 
PCR (Koivunen et al. 2001), was sequenced 
with an ABI 310 Genetic analyzer and the 
Dye Terminator Cycle Sequencing Core kit 
(PE Applied Biosystems, Foster City, CA, 
USA) using as a primer 5´-TAA TAC GAC 
TCA CTA TAG GGC AAG CTG ATA 
AAC CGA TAC AAT-3´.
7. Peptide Synthesis
Peptides hK2p01-hK2p06 (Table 4) were 
synthesized with an Apex 396 DC multiple 
peptide synthesizer (Advanced ChemTech, 
KY, USA) with Fmoc [N-(9-fluorenyl)
methoxycarbonyl] strategy and TBTU/
diisopropylethanolamine as coupling 
reagents. All peptides were synthesized on 
Gly-Wang resin (Advanced ChemTech). 
The side-chain protecting groups used 
in synthesis were t-butyloxycarbonyl 
for tryptophan and lysine, tert-butyl for 
serine and theonine, 2,2,4,6,7-pentame-
thyldihydrobenzofurane-5-sulfonyl for 
arginine, and trityl for glutamine. For 
cysteine both acetamidomethyl and trityl 
protection groups were used. The peptides 
were purified by HPLC (Shimadzu, 
Kyoto, Japan) using a C18 reversed-phase 
column with acetonitrile as eluent [0.1% 
trifluoroacetic acid (TFA), 0-60% acetoni-
trile (ACN) gradient for 60 min]. Alanine 
replacement experiments were done for 
peptides hK2p01-hK2p03 by changing 
each of the amino acids to alanine indi-
vidually.
8. Cyclization of the Peptides
Iodination method was used to cyclize 
peptides containing cysteines with Acm 
(Veber et al. 1972). Into the peptide 
solution with 2 mg/ml concentration in 
50% acetic acid (AcOH) were added 1 M 
HCl (0.1 ml/mg of peptide), which was 
immediately followed by the addition 
of 0.1 M iodine solution in 50% AcOH 
in H2O (5 equiv./Acm). After vigorous 
mixing for 40 min at room temperature, 
the reaction was stopped by adding 0.1 M 
sodium thiosulfate to a final concentra-
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tion. The solution was filtered (0.45 μm) 
and the peptides were purified by HPLC as 
described above.
 Head-to-tail cyclization was 
performed on the resin. The allyl ester 
deprotection was done manually with 
Pd(0) under argon. Mixture of Fmoc 
– peptidyl(resin) – OAll and PhSiH3 
containing the catalyst in a small amount 
of DCM was stirred for 2.5 h at room 
temperature under argon. After washing 
the resin with the catalyst-dissolving 
mixture, 0.5% DIEA in DMF, 0.5% sodium 
diethyl dithiocarbamate in DMF and 
DCM, and drying, the N-terminal Fmoc 
group was removed using 20% piperidine 
in DMF. Head-to-tail cyclization process 
was done twice by the addition of HBTU/
DIEA (8 equiv., 1 : 1, mol/mol) in DMF 
for 2 times for 3 h at room temperature. 
Peptides were released from the Rink resin 
using 95% TFA.
9. Similarity Searches
BLAST searches (www.ncbi.nih.gov/
BLAST) (Altschul et al. 1997) of the hK2 
inhibiting sequences were performed using 
the Swiss-Prot database. 
10. Stability Studies
Initially, stability was studied by using 
modified trypsin (sequencing-grade 
modified trypsin V5113, Promega, 
Madison). Each peptide (400 µg) dissolved 
in 400 µl of 200 mM NH4HCO3 buffer 
(pH 8.0) was mixed with 1 μl of trypsin 
solution (1 mg/ml in NH4HCO3, pH 8.0). 
The peptides were incubated at 37 °C and 
30 μl aliquots were sampled every 30 min. 
Thirty microliters of 2% TFA and 5% ACN 
in water was added, and the samples were 
analyzed by HPLC and by mass spectrome-
try using an ABI QSTAR XL with a MALDI 
interface (AB SCIEX, Framingham, MA, 
USA).
 The stability of the peptides in human 
plasma was studied by mixing 400 μl of 
human male plasma collected into EDTA 
coated vacutainer tubes (BD Biosciences) 
and 400 μl of each peptide (1 mg/ml) in 
PBS (phosphate-buffered saline). The 
peptides were incubated at 37 °C and 100 
μl aliquots were taken after 30 min and 
then every hour up to 4 h. The head-to-
tail cyclic peptides were incubated for 
24 h. The peptide was separated from 
plasma proteins on a centrifugal filter 
device (Microcon YM-10, cut off 10 kDa, 
Millipore, Bedford, MA, USA) by centrifu-
gation at 14,000 rpm using an Eppendorf 
5415 D centrifuge (Eppendorf, Hamburg, 
Germany) for 10 min. Remaining plasma 
protein on the filter was washed with 50 μl 
of 0.1% TFA and 0.1% Tween 20 in H2O 
and centrifuged again for 10 min. The 
filtrates were analyzed by analytical HPLC 
and mass spectrometry.
11. PSA Complexation in Serum
 To estimate the rate of the PSA complex 
formation and to identify the complexes in 
serum, 200 ng of PSA in 1 ml of TBS was 
added to 100 µl of mouse serum and 10 µl 
aliquots, diluted with 90 µl of AB of the 
dual-label IFMA kit (DELFIA Prostatus 
free/total PSA kit), were frozen at time 
points between 0 and 24 h. For further 
purification and identification, PSA (7-24 
µg) in 7-24 µl TBS was added to 300 µl of 
mouse serum. Female human serum was 
used as a control. After incubation for 48 
h, free and total PSA were quantified by 
IFMA.
12. Chromatographies
Free and complexed PSA in serum (250 
µl) were separated by gel filtration on a 
HiLoadTM 16/60 Superdex 200 column 
(Amersham Biosciences, Arlington 
Heights, IL, USA) and eluted with TBS. 
Flow rate was 15 ml/h, and 1-ml fractions 
were collected. Fractions containing 
complexed PSA were identified by IFMA 
and further fractionated by anion-exchange 
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chromatography on a 1-ml Resource Q 
column (Amersham Biosciences) equili-
brated with 10 mM Tris-HCl buffer, pH 8.0, 
containing 8 mM NaN3 (buffer A). Bound 
proteins were eluted with a linear gradient 
composed of 60 ml of buffer A and 60 ml 
buffer A containing 300 mM NaCl. PSA-
containing fractions of 2 ml volume were 
identified by IFMA, pooled and concen-
trated to 1 ml using a Centriplus YM-10 
filtration device (Amicon, Beverly, MA, 
USA).
13. Immunopurification
PSA-complexes in mouse and human 
serum and in chromatographic fractions 
were purified by immunoadsorption using 
Mab 5E4 coupled to Sepharose beads 
(Leinonen et al. 2002; Wu et al. 2004). To 
reduce non-specific binding to the column, 
the fractions were first preincubated for 2 h 
at room temperature with Sepharose beads 
coupled with non-specific mouse antibody 
(I5381, Sigma-Aldrich). The samples were 
then incubated with 30 mg of 5E4-beads 
for 2 h at room temperature on a shaker. 
After washing the beads three times by 
addition of PBS and centrifugation at 8,000 
rpm for 3 min, bound proteins were eluted 
with 24 µl of 0.1% trifluoroacetic acid and 
neutralized with 1 µl of 1 M Tris-HCl.
14. SDS–PAGE and Western Blotting
Immunopurified PSA was boiled 
in reducing SDS-sample buffer and 
separated by electrophoresis on 4-12% 
NuPAGE Bis-Tris gels run in MES buffer 
(Invitrogen, Carlsbad, CA, USA), followed 
by silver staining or transfer of proteins 
to Immobilon-P Transfer Membrane 
(Millipore, Bedford, MA). Non-specific 
binding to the membrane was blocked 
by incubating the filter for 2 h at room 
temperature with 1% bovine serum 
albumin in PBS. The membrane was 
incubated overnight at +4 °C with rabbit 
anti-PSA polyclonal antibody, followed 
by detection with horseradish peroxidase-
conjugated swine anti-rabbit immuno-
globulin G, using enhanced chemilumi-
nescence (ECL) Western blotting detection 
reagents (GE Healthcare, Amersham, UK).
15. Xenograft Tumor Models
The human prostate carcinoma cell lines 
LNCaP and 22RV1 (American Type 
Culture Collection, Manassas, VA) were 
grown in RPMI 1640 medium (Cambrex, 
Verviers, Belgium) containing 10% fetal 
bovine serum, 2 mM L-glutamine, 1.5 g/l 
sodium bicarbonate, 4.5 g/l glucose, 10 
mM HEPES, 1 mM sodium pyruvate, 1% 
non-essential amino acids, penicillin (100 
U/ml), and streptomycin (100 mg/ml) (all 
from Sigma-Aldrich). The cells were kept 
in a humidified incubator at 37 °C with 5% 
CO2.
 Athymic nude mice (NMRI-nu/nu) 
and SCID (severe combined immuno-
deficiency) mice were purchased from 
Taconic (Bomholt, Denmark) and from 
Charles River Laboratories (Wilmington, 
MA, USA). To produce prostate cancer 
xenografts in mice, LNCaP or 22RV1 cells 
(1.5 x 106 per mouse) in 50 µl of 6.7 mM 
phosphate-buffered saline (PBS) without 
Ca and Mg (Cambrex) were mixed with 
50 µl Matrigel basement membrane 
preparation (BD Biosciences, Franklin 
Lanes, NJ, USA). The mixture was injected 
subcutaneously into the flank in the 
abdominal region of 4- to 6-week-old mice. 
The mice were sacrificed before the tumors 
reached a threshold volume of 1,500 
mm3, usually 6-8 weeks after injection of 
the cells. Tumor volume was measured 
with a caliper and calculated according to 
the formula V = width x height x depth 
/ 2. Animal Experiment Board of State 
Provincial Office of Southern Finland has 
approved the study protocols in this work.
16. Immunohistochemical Staining
Mouse tumor tissues were fixed in 10% 
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neutral buffered formalin, embedded in 
paraffin and cut in 5-µm sections. Sections 
were deparaffinized and incubated with 
rabbit anti-PSA polyclonal antibody or 
control rabbit IgG as a negative control. 
For detection HRP-conjugated antirabbit 
polymer (Envision system, Dako) was 
used with 3-amino-9-ethyl-carbazole 
(AEC). The sections were counterstained 
with Mayer’s hemalum solution (Merck, 
Darmstadt, Germany) and mounted with 
Gurr Aquamount (BDH, Poole, UK).
17. Identification of PSA Complexes 
and IGFBP-3 Fragments by Mass 
Spectrometry
IGFBP-3 (1.75 µM) was incubated with 
hK2 (0.25 µM) for 24 h at 37 °C in 20 µl 
of TBS containing 0.06% BSA. Protein 
bands were cut from the silver stained 
gel, alkylated and treated with modified 
trypsin (Promega, Madison, WI, USA) 
for mass spectrometry (Shevchenko et 
al. 1996). IGFBP-3 fragments were con-
centrated using ZipTip pipette tips (µC18 
ZipTip®, Millipore). For LC-MS analysis 
the peptides were separated on a CapLC 
instrument (Waters, Milford, MA, USA) 
with a 0.075 mm x 150 mm C18 column 
(Atlantis dC18, 100 Å, 3 µm, Waters) and 
eluted with a linear gradient of acetonitrile 
(5-50% in 30 min) in 0.1% formic acid. 
Flow rate was 0.3 µl/min and the eluent 
was directly injected into a quadrupole/
time-of-flight hybrid mass spectrometer 
(Q-TOF Micro, Waters) equipped with 
an electrospray ionization (ESI) source. 
Fragmentation spectra of the peptides 
were acquired by colliding doubly or triply 
charged precursor ions with argon collision 
gas at accelerating voltages of 20-70 V.
 Protein and peptide identifications 
were performed automatically with the 
MASCOT search engine (Matrix Science, 
Inc., Boston, MA, USA) using primary 
sequence databases. Spectra were also 
interpreted manually using Biolynx peptide 
sequencing software (Waters) and FASTA 
sequence comparison software (Lipman & 
Pearson 1985).
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1. Identification and Development of 
hK2-inhibiting Peptides (I)
Several rounds of phage display library 
panning with different libraries resulted 
in identification of 6 peptides binding to 
hK2 from libraries X10 and X11 (Table 4). 
Three of these were 10 amino acid long 
linear peptides from X10 library and the 
other three were 11 amino acid long cyclic 
peptides from X11 library. Arginine was 
present in all six peptides. Some common 
motifs can be found between the peptides. 
The peptides hK2p02 and hK2p03 share 
the amino acid sequence of ARRPFP. In the 
other peptides from X11 library arginine is 
located two residues after the first cysteine.
 hK2-binding phage-peptide IFMA, 
where antibody-captured hK2 bound 
phage was traced with europium-
labeled anti-phage polyclonal antibodies, 
confirmed binding of the synthetic 
peptides to hK2. One of the 6 identified 
peptides (hK2p05) showed weak binding 
and it was excluded from further studies. 
The synthetic peptides competed with 
the phage that display same peptides. 
Table 4: hK2-binding peptides identified by phage display.
Code Library Peptide sequence
No. of 
isolates
IC50
1 IC50
2 Ki
3
hK2p01 X10 SRFKVWWAAG 1 3.4 2.6 1.05
hK2p02 X10 AARRPFPAPS 19 30.5 6.5 1.87
hK2p03 X10 PARRPFPVTA 1 162.0 18.6 3.22
hK2p04 X11 CFRQGCWVIT 3
hK2p05 X11 FRTCLRSWACM 6
hK2p06 X11 CYRMPTCMQRD 4
Results
IC50 and Ki values are in µM and refer to inhibition of hK2 enzymatic activity
1with synthetic peptide substrates
2with proPSA
3with IGFBP-3
Furthermore, the cross-inhibition assay 
also showed that peptides hK2p01, hK2p02 
and hK2p03 compete with each other. 
These three peptides were found to inhibit 
the enzymatic activity of hK2 towards a 
synthetic chromogenic substrate (Figure 
5). The specificity was also confirmed 
by studying the effect of peptides on 
the enzymatic activity of several serine 
proteases with similar structure or catalytic 
activity than of hK2. Inhibition of hK2 
by the peptides was dose dependent and 
Lineweaver-burke analyses suggested that 
the peptides are competitive inhibitors. 
Half maximal inhibitory concentrations 
(IC50) for the peptides towards the synthetic 
substrate were 3.4 µM for hK2p01, 30.5 
µM for hK2p02 and 162.0 µM for hK2p03 
(Table 4).
 The residues that are essential for 
inhibition of hK2 were determined by 
making structural modifications and 
testing the effect on inhibition activity 
towards hK2. Alanine replacement and 
38
hK2 and PSA: Functions and Targets for Treatment of Postate cancer
0
0.075
0.150
0.225
0.300
0 5 10 15 20 25 30
no peptide
hK2p03
hK2p02
hK2p01
hK2p01b
A
bs
or
ba
nc
e 
(A
40
5)
Time (min)
sequence trimming of the amino acid 
residues showed that the motif required for 
the inhibitory effect of hK2p01 peptide is 
RFKXWW, while for hK2p02 and hK2p03 
it is ARRPXP. In the alanine replacement 
experiments, changing the first amino acid 
at the N-terminus of the peptide hK2p01 
from serine to alanine actually increased 
the inhibitory efficacy and decreased the 
IC50-value from 3.4 to 2.2 µM. Deletion 
of the N-terminal serine reduced the 
inhibitory activity. The modified hK2p01 
peptide with alanine in the N-terminus 
(hK2p01b) showed the strongest inhibition 
potency towards synthetic peptide 
substrates with a Ki value of 1.41 µM.
Figure 5. Inhibition of hK2 (0.17 µM) by 1000-fold molar excess of hK2-
inhibiting peptides. Absorbance at 405 was measured to observe cleavage of the 
chromogenic substrate S-2302 at 5 min intervals for 30 min (n=12, mean±S.E). 
*, p<0.001 (Student’s t-test).
2. Effect of hK2-inhibiting Peptides 
Towards hK2 on Protein Substrates (I, 
III)
To confirm that the peptides also inhibit 
activity towards protein substrates, we 
studied inhibition of proPSA activation 
by hK2. In our experiments, proPSA was 
activated by hK2, and hK2-inhibiting 
peptides inhibited activation of proPSA 
by hK2 in a dose-dependent fashion. The 
IC50 values for the peptides were 2.6 µM for 
hK2p01, 6.5 µM for hK2p02 and 18.6 µM 
for hK2p03 (mean, n=8, p<0.001 between 
all, Student’s t test). To inhibit hK2 activity 
towards IGFBP-3, the same three hK2-
inhibiting peptides and one modified 
peptide (hK2p01b) were studied. When 
preincubated at three different concentra-
tions, peptides inhibited the enzymatic 
activity of hK2 towards IGFBP-3 in a 
*
*
*
*
*
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dose-dependent fashion as shown by im-
munoassays that measure the intact and 
cleaved IGFBP-3 (Figure 6). The order of 
the inhibitory efficiencies of the peptides 
was the same than those found with the 
synthetic peptide substrates, hK2p01b 
being the most efficient with a Ki value of 
0.28 µM (Table 4). 
Figure 6. The relative percentage of cleaved vs. intact IGFBP-3. Control peptide is previously 
identified 12 amino acid long cyclic PSA-stimulating peptide that does not bind to hK2.
Figure 7. hK2 cleavage sites of IGFBP-3 and fragments generated by hK2.
 We identified the cleavage sites of 
IGFBP-3 generated by hK2 (Figure 7). 
After the digestion by hK2, the IGFBP-3 
fragments were analyzed by mass spec-
trometry and 9 to 35 amino acid long 
eight fragments of IGFBP-3 were found 
(Figure 7). The peptide fragments were 
mostly ending with an arginine, but also 
with lysine and methionine. Cleavage after 
arginine and lysine are in accordance with 
trypsin-like substrate specificity of hK2 
(Deperthes et al. 1996). One fragment 
identified with low confidence score was 
observed to be cleaved after methionine.
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3. Cyclization and Stability Improvements 
of the Peptides (II)
Linear peptides are highly susceptible 
to proteolytic attacks in circulation. We 
found that this was also the case with hK2 
inhibiting peptides, the hK2p01b peptide 
being degraded within minutes. To increase 
stability, the linear peptides were cyclized 
in two different ways; via addition of 
cysteine to both ends to form a disulphide 
bridge, and by cyclization with a peptide 
bond, which is referred as head-to-tail 
cyclization. For the cyclization process, the 
amino acid sequences of hK2-inhibiting 
peptides that are required for inhibition 
were used as scaffolds. The rest of the amino 
acids were replaced by alanine. Several 
derivatives were synthesized by addition 
of alanine residues to both ends to modify 
sizes of the peptides before cyclization. 
Most ARRPAP motif containing peptide 
variants (referred as KLK2a in publication 
III) did not inhibit hK2 after cyclization 
with a disulphide bridge, but one showed 
slight (23%) inhibition. The head-to-tail 
cyclized variants of RFKVWW containing 
peptide (hk2p01b and hK2p01-ht, in 
publication III referred as KLK2b and 
KLK2b-ht, respectively) inhibited hK2 
activity with similar or even higher activity 
than the parent compounds.
 The stability of the hK2 inhibiting 
peptides towards proteolytic degradation 
was studied by incubation with trypsin 
(0.1 µmol/l) and human plasma followed 
by HPLC analyses. Trypsin cleaves peptide 
bonds after lysine and arginine, and human 
plasma is a rich source for proteases. The 
linear hK2p01b was completely degraded 
by trypsin in 30 min, whereas cleavage of 
the cyclic peptides was much slower and 
after 4 h of incubation 43% of hK2p01b-ht 
peptide was intact. In human plasma, the 
linear and the cysteine cyclized forms 
of the peptides were degraded within 30 
min while head-to-tail forms of hK2p01b 
remained intact for 24 h (Figure 8).
Arginine residue in the amino acid 
sequence of the peptides may indicate that 
the peptides could also be substrates for 
hK2 itself. However, we did not observe 
degradation of the peptides by hK2 (data 
not shown).
Search of the proteins/peptides that contain 
similar sequences to those essential for hK2 
inhibition was performed by using BLAST. 
The sequences ARRPXP and RFKXWW 
were searched in the UniprotKB/
Swiss-Prot database of human proteins. 
Several proteins contained the sequence 
ARRPXP of which most were intracellu-
lar proteins or hypothetical proteins with 
evidence at the transcript level. Among 
the most relevant matches were Stromal 
cell-derived factor 1 (UniProt accession 
code P48061), Spasmolytic polypeptide 
(Q03403), serine/threonine protein kinase 
p21-activated kinase 4 (PAK4) (O96013), 
cytokine receptor-like factor 1 precursor 
(O75462), and substance P chain of pro-
tachykinin 1 precursor (P20366). No 
Figure 8. HPLC analyses of hK2p01b-ht 
peptide A) without and with trypsin after 4 
h and B) with human plasma after 30 min 
and 24 h of incubation times.
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proteins containing the RFKXWW motif 
were found.
4. PSA Forms Complexes in Mouse 
Plasma and Serum (IV)
When subcutaneously transplanted into 
nude mice, LNCaP cells and 22RV1 
cells grow tumors, which produce PSA 
that is released into circulation. The 
tumor volumes and the PSA plasma 
concentrations correlated (Figure 9). When 
LNCaP xenograft tumor size reached 1000 
mm3 PSA levels in mouse plasma were 
100-300 µg/l and that in mice bearing 
22RV1 xenograft tumors were 5-8 µg/l. hK2 
serum levels in these LNCaP xenografts 
were up to 2 µg/l (unpublished results). 
During tumor growth, the proportion 
between free and total PSA remained 
fairly constant, 68±7.5% (mean±SD) 
of PSA being complexed. Tumor size 
or total PSA concentrations were not 
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related to the proportion of complexed 
PSA, which was similar in LNCaP and 
22RV1 xenografts. The complexation rate 
was calculated by adding pure PSA to 
mouse serum followed by incubation at 
37 °C and measurement of free and total 
PSA levels in aliquots collected at several 
time intervals. A decrease in free and 
total PSA concentrations were observed 
within 30 min by immunoassay. After 24 
h of incubation, 27% of PSA remained 
free while 36% was in immunoreactive 
complexes and 37% was undetectable, 
most likely in complex with A2M, which 
is not detectable by the immunoassays 
used. Western blotting using anti-PSA 
polyclonal antibody showed that PSA 
formed several complexes in mouse 
serum. The observed bands corresponded 
to 33, 85, 160 and 200 kDa. A weak band 
was observed at 65 kDa (Figure 10). To 
further characterize the complexes, PSA 
added to serum was immunopurified, 
followed by SDS-PAGE. Western blot 
analysis showed that there were no visible 
complexes immediately after addition of 
PSA to the mouse and human serum. After 
18 h PSA was in complexes in both sera. 
PSA complexes in mouse serum were seen 
in the region between 75-230 kDa, while 
in human a strong band at 120 kDa and a 
diffuse band at 200-500 kDa region were 
found. Similar bands were seen at the silver 
staining. To enrich PSA and its complexes 
Figure 9. Total and free PSA values measured from the serum of LNCaP and 22RV1 xenografts. 
Modified and adapted from Hekim et al., Complex formation between human prostate-specific 
antigen and protease inhibitors in mouse plasma Prostate 2010, 70(5), pp.482–490. Reprinted with 
permission.
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Figure 10. Flow chart for identification of PSA complexes in mouse serum. The collected fractions 
from chromatography steps are shown in boxes with a dashed line. Except for human PSA, all 
proteins are of mouse origin
1 The peptides identified by MS belong to the region between N-terminus and bait region.
2 The identified peptides could be derived from members of the α1-antitrypsin family.
3 Roughly equal amounts of PSA and α1-antitrypsin 1-5 were found by MS.
4 Minor amounts as compared to PSA.
5 One of the identified peptides is found in the C-terminal part, which is cleaved upon the 
activation of the serpin
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before immunopurification, gel filtration 
and ion exchange chromatography were 
performed. After immunopurification 
and SDS-PAGE, silver staining revealed 
4 bands of sizes between 37-93 kDa. 
These bands together with the two other 
bands from the silver staining without 
immunopurification were in-gel trypsin 
digested and identified by MS/MS. The 
analyses showed that the bands at the 
sizes of 58 and 93 kDa contained mostly 
serpins from α1-antitrypsin family, and 
smaller bands of 37 and 40 contained both 
members of α1-antitrypsin family and PSA. 
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Among proteases produced by the prostate, 
hK2 and PSA are the most organ specific 
and most abundant (Wang et al. 1981; 
Schedlich et al. 1987; Shaw & Diamandis 
2007). Both enzymes have been suggested 
to play roles in tumor growth in prostate 
cancer (Borgoño & Diamandis 2004). PSA 
exhibits antiangiogenic properties and 
may thus reduce tumor growth, whereas 
hK2 may favor tumor growth by cleaving 
or activating growth factor regulators, 
such as IGFBP-3 and PAR2, and increase 
metastasis by degrading ECM (Koistinen 
et al. 2008). In a previous (Wu et al. 2000) 
and present study (I) we have identified 
peptides that bind specifically to PSA and 
hK2, and enhance the enzymatic activity 
of PSA or inhibit hK2, respectively. These 
peptides are potential drugs for therapy 
of prostate cancer. Inhibition of hK2 by 
specific peptides may also slow down 
tumor growth. However, in order to 
study the effect of the peptides in vivo the 
stability of the peptides usually have to be 
improved. Moreover, to develop medical 
interventions based on modulation of the 
activity of PSA or hK2 it is necessary to 
learn about the behavior of these proteases 
in the tumor microenvironment and in the 
circulation using animal models of prostate 
cancer. 
1. Identification and structure of peptide 
inhibitors of hK2 (I)
In this study, novel hK2-binding peptides 
were identified using phage display 
technology. Three linear peptides that 
inhibit the enzymatic activity of hK2 were 
found. By using same method, specific 
peptides for PSA have previously been 
identified in our laboratory (Wu et al. 
2000). The PSA-specific peptides were 
identified in cyclic libraries and they 
enhanced the enzymatic activity of PSA. 
No peptides were identified when PSA or 
hK2 were directly adsorbed to the plastic 
wells. A critical factor in identification 
of both PSA- and hK2-specific peptides 
was to capture the target protein using 
antibodies for the screening process. With 
this strategy we were able to expose the 
active site of the enzymes to the peptides 
displayed by phage and to identify peptides 
that bind to this region. Despite the high 
structural similarity between PSA and hK2 
and the same antibody used to capture, 
the peptides identified with these enzymes 
did not contain any common motifs. In 
the case of enzymatic activity modulating 
peptides, this is apparently related to the 
different substrate specificity of these 
enzymes. Moreover, the peptides binding 
to PSA stimulated its enzymatic activity, 
while those binding to hK2 inhibited.
 All of the hK2 binding peptides 
contained arginine residue. This is not 
surprising as arginine is located at the P1 
position of hK2 substrates (Cloutier et al. 
2002). hK2 probably requires arginine with 
an amino acid before for initial binding 
to the catalytic cleft. When arginine is 
replaced or deleted, the peptides completely 
lost their inhibitory effect towards hK2 
confirming the necessity of arginine at a 
certain position. Replacement or deletion 
of the other residues reduced this inhibitory 
effect or some residues could be completely 
replaced or discarded without significant 
effect on activity. These studies revealed 
the motif required for the inhibitory 
activity. Two inhibiting peptides contained 
almost identical motif ARRPXP. The motif 
of the more potent peptide inhibitor was 
RFKXWW, but for the maximal effect 
Discussion
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the motif requires at least one amino acid 
before arginine. In the original peptide, the 
first amino acid was serine, but alanine-
scanning studies showed that alanine in 
this position actually increases the potency.
 Phage screening was performed 
using linear and constraint cyclic peptide 
libraries, but peptides binding to hK2 were 
only found with linear phage libraries. 
Interestingly, three of the peptides that 
were identified with the X11 library 
contained two cysteine residues and they 
are likely to be cyclic. In these peptides, 
like in the other ones, arginine was the 
2nd amino acid after cysteine and the 
peptides contained the CXR motif. These 
three cysteine containing peptides, with 
the exception of hK2p06, did not show any 
effect on the enzymatic activity of hK2. No 
peptides were identified in cyclic libraries 
used for screening. The reason for this 
may be because the constraint libraries 
contained 3, 7, 8 or 11 amino acids between 
the cysteine residues, whereas there were 
4 or 5 amino acids in the cyclic peptides 
identified. 
 Amino acid sequence similarity 
search of the hK2-inhibitory peptides was 
performed by using BLAST and found 
several hits for the peptide motif ARRPXP. 
However, some of these proteins are not 
expressed by prostate and the rest are 
intracellular, therefore, their interaction 
with hK2 is unlikely. No proteins containing 
the motif RFKXWW were found.
2. Specificity and Stability of the hK2-
inhibiting Peptides (I, II)
In our study, hK2-inhibitory peptides were 
specific for hK2 and did not show any effect 
on several other proteases. Although active 
forms of PSA and hK2 share 79% identical 
amino acid sequence, the peptides did 
not either bind to or affect the enzymatic 
activity of PSA. This was not surprising, 
as PSA has a different substrate specificity. 
The assay where the phage peptides 
compete with synthetic peptides showed 
that the hK2-inhibitory peptides bind to 
the same or adjacent site. The peptides are 
competitive inhibitors and inhibit hK2 in a 
dose-dependent fashion. 
 The identified hK2-inhibitory 
peptides are linear, which makes them 
highly susceptible towards proteolytic 
attacks and especially to exopeptidases 
that are active in human plasma (Sato et al. 
2006). Furthermore, the peptides contain 
arginine, which makes them potential 
substrates for trypsin and trypsin-like 
proteases including hK2 itself. Indeed, 
trypsin cleaved the peptides very efficiently 
although hK2 did not. We found that the 
hK2-inhibitory peptides were rapidly 
degraded in plasma. For the peptides to be 
used for in vivo studies, the stability must 
be improved so that they can withstand 
proteolytic attack at least until they bind to 
their target and inhibit it. 
 The stability of peptides can be 
increased by several methods including 
PEGylation (using PEG chains as a 
carrier), retro-inversion and cyclization. 
Conjugation of PEG molecules to N- or C- 
terminus or to both termini of the peptide 
can protect the peptide from exopeptidases 
(Veronese & Pasut 2005). By addition of 
multiple PEG molecules (e.g., 5 kDa) to the 
peptide, it is possible to make it big enough 
(>30 kDa) to reduce renal clearance 
from the circulation (Sato et al. 2006). 
As a carrier molecule PEG also has been 
shown to have favorable properties such 
as high water solubility, high mobility and 
low immunogenicity (Werle & Bernkop-
Schnürch 2006). Retro-inversion, i.e., 
synthesizing the peptide with D-amino 
acids instead of natural L-amino acids, can 
also improve stability towards proteases. 
For example, octreotide, a 14 amino acid 
long synthetic peptide drug based on 
somatostatin used to treat gastrointestinal 
tumors, has half life of few minutes. 
This has been extended up to 1.5 h by 
shortening the sequence to 8 amino acids 
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and replacing them with D-amino acids 
(Harris 1994; Werle & Bernkop-Schnürch 
2006). Modification for improving the 
half-life of peptides require optimization. 
We used cyclization and retro-inversion 
methods to increase the stability of the 
peptides. Retro-inversion of the peptides 
abolished their inhibitory activity towards 
hK2 (unpublished). Cyclization of the 
peptides was done by adding cysteine 
residues to form disulfide bridges or head-
to-tail cyclization via a peptide bond. In 
both types of cyclization the peptides kept 
their inhibitory properties, furthermore, 
head-to-tail cyclized peptide was relatively 
stable against tryptic digestion and 
proteolytic degradation in human plasma. 
 Diffusion from circulation into tissues 
may take time. Therefore, more stable 
peptide-drug may have better therapeutic 
activity. However, it is also important that 
the peptide-drug clears out from the human 
body afterwards. Accumulation in the liver 
or kidney may cause organ damage. Thus, 
the half-life of therapeutic peptides need to 
be optimized. In our study the size of the 
hK2-inhibiting peptide is small enough to 
be cleared through the kidneys. However, 
the excretion can also be too rapid, i.e., 
before reaching the target tissue. In these 
cases, PEGylation or conjugation with a 
larger molecule, such as albumin, may be a 
solution for both stability and clearance. 
3. Inhibition of hK2 Activity Towards 
Protein Substrates by hK2-inhibiting 
Peptides (I, IV)
We studied the inhibitory effect of the 
peptides towards proPSA activation and 
IGFBP-3 cleavage. For both of these protein 
substrates the peptides inhibited hK2 in 
a dose-dependent fashion. The order of 
inhibitory efficacies of the peptides towards 
hK2 were the same than with synthetic 
substrates. This is important as active PSA 
has been suggested to take part in the 
early development of prostate cancer and 
also play a role in degradation of the ECM 
(Webber et al. 1995). When overexpressed 
in prostate tumors, hK2 may promote 
tumor growth by digesting IGFBP-3, 
which regulates cell proliferation via IGF-
system (Jones & Clemmons 1995). It may 
also exert an apoptotic effect independent 
of IGF-system (Rajah et al. 1997; Boyle 
et al. 2001; Silha et al. 2006). Therefore, 
inhibiting hK2 activity towards proPSA 
and IGFBP-3 may be favorable in treating 
or slowing down prostate tumor growth. 
However, it should also be noted that hK2 
is not the only enzyme that can cleave 
IGFBP-3. Trypsin and PSA, which are both 
expressed in prostate cancer, also cleave 
IGFBP-3 (Cohen et al. 1992; Koistinen et 
al. 2002). PSA cleaves IGFBP-3 with less 
efficiency compared with trypsin and hK2 
(Koistinen et al. 2002). 
 In addition to the confirmation of 
IGFBP-3 cleavage by hK2, we identified 
the IGFBP-3 fragments generated by hK2. 
Identification of the hK2 cleaved IGFBP-3 
fragments in serum may facilitate prostate 
cancer diagnosis. Because of their different 
substrate specificities, the fragments 
generated by PSA and hK2 are different 
(Okabe et al. 1999). Since in advanced 
malignant prostate tissue expression of hK2 
is increased and PSA is reduced, there may 
be increased amounts of hK2-generated 
IGFBP-3 fragments that has tryptic-
cleavage sites rather than chymotryptic-
cleavage sites. 
 The natural substrates of hK2 suggest 
a role in prostate tumor biology. Based 
on substrate specificity, hK2 may act on 
proteolytic cascade increasing proliferation 
and tissue invasion (Rittenhouse et al. 1998; 
Koistinen et al. 2008). hK2 is also involved 
in other tumor promoting mechanisms. 
It can stimulate cell proliferation through 
ERK1/2 pathway by activating PAR2 (Mize 
et al. 2008). Therefore, studies on the effect 
of the hK2-inhibiting peptides also on the 
PAR2 activation pathways are justified.
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4. PSA and hK2 in Prostate Cancer 
Xenograft Models LNCaP and 22RV1 
(IV)
Several PSA-expressing tumor cell lines 
can be transplanted into mice to establish 
animal models of prostate cancer (van 
Weerden & Romijn 2000). We produced 
LNCaP and 22RV1 xenografts and showed 
that blood PSA levels correlate with the 
volume of the tumor, which confirms 
PSA as a valid surrogate marker for the 
followup of tumor growth. In the serum of 
LNCaP xenografts, by using immunoassay, 
we were able to detect hK2, suggesting this 
model is suitable also for hK2-targeting 
studies.
 When using these xenograft models 
it is important to know the fate of PSA 
in circulation, and especially whether 
it is enzymatically active or inactivated 
by complexation with serpins and other 
inhibitors. This information is also useful 
for the development of PSA-based medical 
interventions, in which PSA is targeted or 
the enzymatic activity of PSA is utilized 
(Williams et al. 2007; Denmeade et al. 
1998). In this study, we showed that PSA 
behaves similarly in the circulation of 
human and mice. Like in human plasma, 
active PSA released into the circulation 
from the xenograft tumors rapidly forms 
complexes with protease inhibitors in 
mouse plasma. After addition of PSA to 
mouse serum, complexation occurred 
within 30 min, which is also similar to the 
rate in human plasma (Zhang et al. 1995; 
Christensson et al. 1990). Immunoassay 
of total and free PSA showed 70% to 
be complexed and 30% free. Around 
30% of the added PSA was undetectable 
indicating complexation with A2M. These 
proportions are similar to those found in 
human plasma of prostate cancer patients 
(Finne et al. 2000b; Lilja 1993). When we 
identified the composition of these PSA 
complexes by tryptic digestion and mass 
spectrometry, we found that the major 
PSA complex was with A2M and serpins of 
the AAT family. In humans, the major PSA 
complexes are PSA-ACT and PSA-A2M 
(Christensson et al. 1990; Lilja et al. 1991; 
Stenman et al. 1991; Zhou et al. 1993). 
PSA also forms complexes with AAT 
in human serum (Stenman et al. 1991; 
Zhang et al. 1999), but the proportion is 
low compared to that with ACT. Serpins 
contain a reactive center loop (RCL) with a 
recognition site that is specifically cleaved 
by various serine proteases (Forsyth et al. 
2003). Upon cleavage of the RCL, serpins 
change conformation and form a covalent 
bond with the enzyme. This mechanism 
is called “suicide mechanism” due to the 
irreversible structural change of the serpin 
after complex formation. Mouse AATs 
and ACT orthologue serpin A3N contain 
different recognition sites in their RCL 
than human AATs and ACT. This explains 
why PSA in mouse serum forms complexes 
with mouse AATs, but not with mouse 
ACT. 
5. Peptide Based Targeting and Therapies 
for Prostate Cancer (I, III, IV)
Therapeutic peptide drugs currently in 
the pharmaceutical markets are used to 
treat various diseases (Kelley 1996; Loffet 
2002; Stevenson 2009). Furthermore, 
there are hundreds of peptides in the 
drug development pipeline and in clinical 
trials (Vlieghe et al. 2010). The increasing 
utility of peptides is related to their high 
specificity towards their targets (Lien & 
Lowman 2003). However, the short half-
life of peptides is a main challenge for their 
therapeutic use, but modified peptides can 
be very useful drugs (McGregor 2008).
 hK2-inhibiting peptides may have 
significant therapeutic value as increased 
expression levels of hK2 is associated with 
aggressive stages of prostate cancer (Darson 
et al. 1997; Lintula et al. 2005). Studies 
have suggested that enzymatic activity of 
hK2 plays a role in the tumor progression 
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by degrading components of the ECM 
and proteins involved in regulation of cell 
growth (Clements et al. 2004). Therefore, 
inhibition of hK2 by these peptides may 
slow down the growth of prostate cancer 
and prevent formation of metastases. We 
have shown that hK2-inhibitory peptides 
inhibit IGFBP-3 degradation and proPSA 
activation. However, these findings need 
to be validated in cell and animal model 
studies. In order to use in animal studies, 
the peptides need to be stable in circulation 
and have an acceptable clearance rate. As 
part of this study, we have improved the 
stability of the peptides by cyclizing them, 
but for studies on the effect on tumor 
growth, they probably need to be modified 
to have a longer half-life. 
 Making a drug out of a peptide is a 
long and challenging process. Although we 
have made a major advancement by making 
them stable in plasma, there still remain 
many steps before they can be tested for 
prostate cancer therapy.
 In prostate cancer detection these hK2-
inhibiting peptides also have a potential use 
in tumor imaging, which permits the direct 
visualization of targets. To a certain extend 
prostate cancer metastases express hK2 
(Darson et al. 1999) and PSA (Stein et al. 
1984). Thus, the peptides for hK2 or PSA can 
be used to target and image these prostate 
originated tumor cells. For example; when 
radiolabeled, the peptides can be tracked 
by positron emission tomography (PET) 
scan and the tumor or metastatic site can be 
observed. The advantages of hK2-inhibiting 
peptides would be not only binding, but 
also have a therapeutic effect on the target 
tumor tissue. Although secreted target 
proteins are not the best choice for imaging, 
high concentrations of hK2 or PSA around 
the source tissue might make the imaging 
possible. 
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By using phage display we identified 
several inhibitory peptides that are specific 
for hK2, a protease produced abundantly 
by prostate. The peptides were found 
to inhibit hK2 activity against synthetic 
peptide substrate and physiological 
protein substrates. Relevant to prostate 
cancer progression, the peptides inhibited 
activation of proPSA and proteolysis of 
IGFBP-3 by hK2. The required motifs for 
their inhibitory activity were determined 
by chemically synthesizing structural 
variants of the peptides and testing their 
effect on the enzymatic activity of hK2. As 
a result of these studies we increased the 
potency of the most efficient inhibitory 
peptide. We could also reduce the size 
of the peptide from 10 to 8 residues by 
keeping only the amino acids necessary 
for the inhibitory effect. The stability of 
this peptide in plasma was improved by 
cyclization in a head-to-tail fashion. Hence, 
the stability of the peptide in plasma was 
extended significantly. This will allow us 
to study the effect of the peptide on tumor 
growth in xenograft models, like LNCaP 
model that was found to produce both PSA 
and hK2, and was validated regarding the 
complexation of PSA in circulation. 
 As hK2 promotes tumor growth 
by degrading ECM and IGFBP-3, and 
by activating PAR2 and uPA, specific 
inhibition of the enzymatic activity of 
hK2 by these peptides may inhibit or slow 
down the tumor growth. Furthermore, the 
expression of hK2 is limited to prostate, 
therefore, its inhibition does not need to be 
associated with adverse side effects. Thus, 
hK2-inhibiting peptides may be potentially 
useful for targeting and treating prostate 
cancer.
Conclusions
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